CLINICAL  STUDY  PROTOCOL
A Multicenter , 2 Part Study to Assess the Efficacy and Safety of  
Acthar Gel in Subjects With Rheumatoid Arthritis With Persistently 
Active Disease 
Protocol Number :  MNK 14294063
Date of Original Pr otocol :  24 May 2016
Date of Pr otocol Revision: 04August 2016
Mallinckrodt ARD Inc .
675 McDonnell Boulevard
Hazelwood, MO 63042
United States of America

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 2of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtTable of Contents
1DISCLOSURE ST ATEMENT ......................................................................................... 7
1.1 Restricted Distribut ion of Docum ents.......................................................................... 7
2CONT ACTS ................................................................................................................... 8
2.1 Emergency Cont acts.................................................................................................... 8
2.2 Addit ional Contacts ..................................................................................................... 9
3SPONSOR SIGNA TURE .............................................................................................. 10
4INVESTIGA TOR SIGNA TURE ................................................................................... 11
5ABBREVIA TIONS ....................................................................................................... 12
6SYNOPSIS ................................................................................................................... 14
7STUDY  SCHEMA TIC AND SCHEDULE OF EVENTS .............................................. 17
7.1 Study  Schemat ic........................................................................................................ 17
7.2 Sche dule of Study  Events .......................................................................................... 18
8ETHICAL  CONSIDERA TIONS ................................................................................... 20
8.1 Institutional Review Board/Independent Ethics Committee ....................................... 20
8.2 Ethical Conduct of the Study ..................................................................................... 20
8.3 Subject Informat ion and Consent ............................................................................... 20
9BACKGROUND INFORMA TION AND RA TIONALE ............................................... 21
9.1 Overview .................................................................................................................. 21
9.2 Product Descript ion................................................................................................... 24
9.3 Dosage and Administrati on....................................................................................... 25
9.4 Rationale ................................................................................................................... 25
9.5 Risk/Benefit .............................................................................................................. 26
10OBJECTIVES ............................................................................................................... 26
10.1 Primary O bject ive..................................................................................................... 26
10.2 Secondary  Object ives................................................................................................ 26
10.3 Exploratory  Objectives .............................................................................................. 26
11STUDY  DESIGN .......................................................................................................... 27

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 3of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt11.1 Descrip tion................................................................................................................ 27
11.2 Approximate Duration of Subject Participat ion......................................................... 27
11.3 Approximate Duration of Study ................................................................................ 28
11.4 Approximate Number of Subjects ............................................................................. 28
12SELECTION OF SUBJECTS ....................................................................................... 28
12.1 Inclusio n Cri teria...................................................................................................... 28
12.2 Exclusio n Cri teria..................................................................................................... 30
12.3 Screen Failure ........................................................................................................... 32
13PRIOR AND CONCOMIT ANT MEDICA TION/NONDRUG THERAPIES ................. 32
13.1 Prohibited Conco mitant Medi cations/Nondrug Therapies .......................................... 32
14PROCEDURES/ASSESSMENTS ................................................................................. 33
14.1 Screening Visit (Study Days -28 to -1) Procedures/Assessments ................................ 33
14.2 Baseline Visit (W eek 0) and Fi rst Dose Procedures/Assessments ............................... 34
14.3 Week 4 (± 5 day s)and 8 (± 5 day s) Procedures/Assessments ..................................... 35
14.4 Week 12 (± 2 day s) Procedures/Assessments ............................................................. 36
14.5 Week 16 (± 5 day s) and 20 (± 5 day s) Procedures/Assessments .................................36
14.6 Week 24 (± 5 day s)/Early T erminat ion Procedures/Assessments ................................ 37
14.7 Follow-up Visit Procedures/Assessments ................................................................... 38
14.8 Unscheduled Visit Procedures/Assessments .............................................................. 38
15INVESTIGA TIONAL  MEDICINAL  PRODUCT (Study  Drug) ..................................... 38
15.1 Methods of Assigning Subjects to Treatment Groups ................................................. 38
15.2 Emergency Ident ificat ion of Invest igational M edicinal Product .................................39
15.3 Dosing Procedures .................................................................................................... 39
15.3.1 Treatment Discont inuat ion.................................................................................... 40
15.4 Storage of Clinical Supplies ...................................................................................... 41
15.5 Drug Accountabilit y.................................................................................................. 41
15.6 Com pliance Moni toring ............................................................................................ 41
16SAFETY  ASSESSMENTS AND PROCEDURES ......................................................... 41
16.1 Adverse Events ......................................................................................................... 42
16.2 Medical and Surgical History .................................................................................... 42

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 4of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt16.3 Current Medical Condit ions...................................................................................... 42
16.4 Physical Examinat ion................................................................................................ 42
16.5 Height and W eight ................................ ..................................................................... 43
16.6 Vital Signs ................................................................................................................ 43
16.7 Clinical Laboratory  Tests (Chemistry , Hem atology, Urinalysis, HbA1c, Hepat itis 
Serol ogy, IGRA, and Pregnancy T ests) ...................................................................... 43
17EFFICACY  ASSESSMENTS ........................................................................................ 45
17.1 28 Joint Coun t........................................................................................................... 45
17.2 Subject Com pleted Efficacy Quest ionnaires .............................................................. 46
17.3 Physician Co mpleted Efficacy Quest ionnaires ........................................................... 46
17.4 ESR and CRP ............................................................................................................ 46
.......... 46
20STATISTICAL  METHODS AND PLANNED ANAL YSIS ........................................... 47
20.1 General Considerations ............................................................................................. 47
20.2 Analysis Populat ions.................................................................................................48
20.3 Endpoints ................................ .................................................................................. 48
20.3.1 Primary Efficacy Endpo int.................................................................................... 48
20.3.2 Secondary  Efficacy Endpo ints............................................................................... 48
20.3.3 Secondary  Safety Endpo ints.................................................................................. 48
20.3.4 Exploratory  Endpo ints........................................................................................... 48
20.3.5 Subject Characterist ics.......................................................................................... 49
20.3.5.1 Dem ographics .................................................................................................... 49
20.3.5.2 Medical and Surgical History ............................................................................. 49
20.3.5.3 Prior and Concomi tant Medicat ions................................................................... 49
20.3.5.4 Subject Disposit ion and Exposure to Study  Drug ............................................... 50
20.3.6 Safety Analysis ...................................................................................................... 50
20.3.6.1 Adverse Events .................................................................................................. 50
20.3.6.2 Clinical Laboratory  Tests................................................................................... 50

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 5of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt20.3.6.3 Vital Signs ......................................................................................................... 50
20.3.6.4 Other Safet y Analysis ........................................................................................ 50
20.3.7 Efficacy Analysis .................................................................................................. 50
20.4 Pharmacodynamic Analysis ....................................................................................... 51
20.5 Pharmacoeconomic Analysis ..................................................................................... 51
20.6 Interim Analysis ........................................................................................................ 52
20.7 Statistical Power and Sample Size Considerat ions..................................................... 52
20.8 Deviat ions From Stati stical Analysis Plan .................................................................52
21ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS ........................................ 52
21.1 Safety........................................................................................................................ 52
21.2 Definit ions................................
................................................................................ 52
21.3 Adverse Event and Serious Adverse Event Classifications ......................................... 54
21.4 Adverse Event and Serious Adverse Event Recording and Reporting ........................ 56
21.5 Adverse Events of Special Interest ............................................................................ 58
21.6 Pregnancy Reporting .................................................................................................58
22SUBJECT DISCONTINUA TION OR WITHDRA WAL................................................ 59
22.1 Subject W ithdrawal ................................................................................................... 59
23STUDY  SUSPENSION, TERMINA TION, AND COMPLETION .................................61
24PROTOCOL  AMENDMENTS ..................................................................................... 61
25QUALITY CONTROL  AND ASSURANCE .................................................................61
25.1 Study  and Study  Site Discont inuat ion Cri teria........................................................... 61
26DIRECT ACCESS, DA TA HANDLING, AND RECORD -KEEPING ........................... 62
26.1 Invest igator ............................................................................................................... 62
26.2 Sponsor ..................................................................................................................... 63
27SUBJECT INJUR Y....................................................................................................... 63
28RECORDS RETENTION ............................................................................................. 63
29BIOLO GICAL  SAMPLES ............................................................................................ 63
30PUBLICA TION POLICY ............................................................................................. 64
30.1 Sponsor ’s Publication Policy ..................................................................................... 64

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 6of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt30.2 Invest igator ’s Ability to Publish ................................................................................ 64
31REFERENCES ............................................................................................................. 65
32Attachm ents.................................................................................................................. 71
32.1 Attachm ent 1: Clinical Laboratory  Tests.................................................................... 71
List of T ables
Table 7 -1: Schedule of Study  Events ............................................................................. 18
Table 12 -1       Allowed DMARDs ...................................................................................... 29
Table 21 –1: Adverse Event Relat ionships ................................ ........................................ 55
Table 21 –2: Adverse Event Severit y Grades ................................ .................................... 55
Table 21 –3: Reporting Requirements for Adverse Events ................................................ 56
List of Figures
Figure 7-1: Study  Overview ................................ ........................................................... 17

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 7of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt1DISCLOSURE ST ATEMENT
1.1 Restricted Distribution of Documents
This document contains informat ion that i s confident ial and proprietary  to the sponsor . This 
inform ation is being provided to the investigator solely for the purpose of evaluat ing and/or 
conducting a clinical study  for the sponsor . The investigator may discl ose the contents of this 
docum ent only  to study  personnel under his/her supervisio n, inst itutional review boards 
(IRBs) /independe nt ethics co mmittees (IECs) , or duly authorized representatives of 
regul atory  agencies for this purpose under the condit ion that they  maintain confidentialit y. 
The contents of this document may not be used in any other clinical study , disclosed to any  
other person or entit y, or published wit hout the prior written permissio n of the sponsor . The 
foregoing shall not apply to disclosure required by any regulations; however, the invest igator
will give prompt notice to the sponsor of any such disclosure. All othe r nonpublic 
inform ation provi ded by  the sponsor, as well as any informat ion that may be added to this 
docum ent, also is confident ial and propri etary  to the sponsor and must be kept in confidence 
in the same manner as the contents of this document.

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 8of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt2CONT ACTS
2.1 Emergency Contacts
Role in Study Name Contact Information 
Primary  Contact:
Medical Monitor , MD, PhD
PRA Health Sciences
4130 ParkLake Ave. 
Suite 400 Raleigh, 
North Carolina 27612 
United States of AmericaTelepho ne: 
E-mail: (not for emergencies): 
Secondary Contact: 
Back -Up Medical 
MonitorMD
PRA Health Sciences
Bollingbrook, IL
United States of AmericaTelepho ne: 
E-mail :(not for emergencies): 
Please see next page for addit ional telephone contact numbers in Section 2.2.
Please see Section21.4 for detailed informat ion regarding the Serious Adverse Event (SAE) 
Reporting Requirements for this study .
SAE reporting fax: +1314-654-5759
SAE confirmat ion email: GlobalPV@mallinckrodt.com

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 9of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt2.2 Additional Contacts
Role in Study Name Contact Information
Sr. Clinical Trial 
Manager MS, 
M.Phil .Telepho ne:
E-mail: 
Clinical Technical
Lead  MD Telepho ne: +
Cell pho ne:
E-mail: 

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 11of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt4INVESTIGA TOR SIGNA TURE 
My signature confirms that the clinical study  will be conducted in accordance with the 
protocol  and applicable laws and other regulations including, but not limited to, the 
International Conference on Harmonisation (ICH) Gui deline for Good Clinical Practice 
(GCP), the US Code of Federal Regulations (CFR) (where appropriate) , all applicable
national and local regulat ions, protecti ons for privacy, and generally  accepted ethical 
principles such as the Declarat ion of Helsinki .
Nothing in this document is intended to limit the authority  of a physician to provi de 
emergency medical care.
Invest igator ’s Signature Date of Si gnature
(DD M onth YYYY)
Invest igator ’s Nam e and Tit le (print)

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 12of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt5ABBREVIA TIONS
Abbr eviation Term
2x/week Twice a week
ACTH Adrenocorti cotropi c hormone
ACR American Co llege of Rheumatology
ACR20 20% improvement in ACR criteria
ACR50 50% improvement in ACR criteria
ACR70 70% improvement in ACR criteria
AE Adverse e vent
ALT A lanine aminotransferase
ANC Absolute neutrophil count
AST Aspartate aminotransferase
CDAI Clinical Disease Act ivity Index
CFR Code of Federal Regulat ions
CIA Collagen- induced arthrit is
CRP C-reactive protein
CTX -I C- terminal crosslinking telopeptide of Type I collagen
CTX -II C-terminal crosslinking telopeptide of Type II collagen
DA Disease act ivity
DMA RD Disease modifying ant irheumatic drug
eCRF Electronic case report form
DAS28 -ESR Disease Activit y Score with 28 j oint count and ESR
ED Emergency Department
ESR Erythrocyte sedimentati on rate
EULAR European League Against Rheumat ism
FACIT-F Funct ional Assessment of Chronic Illness Therapy- Fatigue
FDA Food and Drug Administration
GCP Good Clinical Pract ices
HAQ -DI Health Assessment Questionnaire -Disabili ty Index
HbA1c Glycosylated hemoglobin
HBsAg Hepati tis B surface a ntigen
HBcAb Hepati tis B core a ntibody
HCV Hepati tis C v irus ant ibody
HCV PCR Hepati tis C vi rus polymerase chain r eaction
HIPAA Health Insurance Portabilit y and Accountabilit y Act
ICF I nform ed consent f orm
ICTP I collagen telopepti de
ICH International Conference on Harmonisation
ID Ident ification
IEC Independent Ethics Committee
IGRA Interferon gamma release a ssay
IMP Invest igational medicinal product

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 13of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtAbbr eviation Term
IRB Institutional Review Board
IXRS Interactive Phone/W ebResponse System
JAK Janus kinase
LDA Low di sease act ivity
MCR Melanocorti n receptor
mITT Modified intent to treat
MM Medical mo nitor
MTX M ethotrexate
OPG Osteoprotegerin
PINP N-terminal propepti de of T ype I collagen
QD Per day , daily
RA Rheumatoid arthri tis
RANKL Receptor activator of nuclear kappa β ligand
SAE Serious adverse event
SC Subcutaneous
TB Tuberculosis
TNF -α Tumor Necrosis Factor -alpha
TEAE Treatment -emergent adverse event
U Unit( s)
US United States of America
ULN Upper limitofnormal
VAS Visual Analog Scale
WPAI Work Productivit y and Act ivity Impairment Questi onnaire

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 14of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt6SYNOPSIS
Study Title: A Multicenter, 2 Part Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With 
Rheumatoid Arthritis With Persistently Active Disease 
Protocol Number: MNK 14294063 Type: Phase 4(US)/Phase 2 (all other countries)
Condition/Disease: Rheumatoid Arthritis
Approximate Number of Subject s: 232 Approximate Duration of Subject Participation: 32weeks
Approximate Number of Study Centers: 100
globallyApproximate Duration of Study: 4.5years
Design: 
This is a2 part multicenter stud yto examine the effect of Acthar in adult subjects with rheumatoid arthritis 
(RA)with persistently active disease . In Part 1 (Open Label Period) ,following a screening period of up to 
28 days, allsubjects will receive open label treatment with 1 mL (80 U nits [U ])of  Acthar Gel(hereafter 
referred to as Acthar) subcutaneously (SC) 2 times per week ( 2x/week )for 12 weeks. After 12 weeks of 
treatment with Acthar, subjects will be evaluated for treatment response using the Disease Activity Score in 
28 Joints -Erythrocy te Sediment ation Rate (DAS28 -ESR). Subjects who have achieved low disease activity 
(LDA) ,defined as DAS28 -ESR < 3.2 ,will enter a double -blind randomized maintenance period (Part 2) and be 
randomized in a 1:1 ratio to receive either Acthar 1 mL (80 U) SC ormatching placebo 1mLSC 2x/week for an 
additional 12 weeks. Subjects who do not achieve LDA at W eek 12 will be discontinued from further study 
participation. All subjects will have a follow -up visit 28 (± 2) daysafter the last dose of study  drug , regardless 
of treatment group.
Objectives:
Primary Objective
Toassess the efficacy of Acthar given as a 1 mL (8 0 U)dose 2x/week for 12 weeks as determined by 
DAS28 –ESRin subjects with RA with persistently active disease .
Secondary Objectives
To assess the safety and tolerability of Acthar in subjects with RA with persistently active diseas e
.
To assess the efficacy of Acthar in maintaining LDA in subjects with RA with persistently active 
disease who have achieved LDA after 12 weeks of treatment.
Exploratory Objecti ves


Entry Criteria: 
Male or nonpregnant, nonlactating female subjects 18 years of age or older meeting the definition of RA in 
accordance with the 2010 Rheumatoid Arthritis Classification Criteria (American College of Rheumatology 
[ACR] /European League Against Rheumatism [EULAR] Collaborative Initiative .Subjects must have active 
disease defined as a score of 3.2 on DAS28 -ESR at screening and baseline .Subjects must have been on a 
corticosteroid for at least 12 weeks prior to screening and on a stable dose of 5 to 10 mg of prednisone (or 
prednisone equivalent) for at least 4 weeks prior to screening . In addition to prednisone subjects must be on a 
stable dose of ≤ 20 mg per week of methotrexate (MTX ) and a stable dose of 1 biologic or nonbiologi c disease 
modifying anti rheumatic drug (DMARD ),orbe on a stable dose of 1 biologic DMARD for at least 12 weeks 
prior to screening. Subjects with current rheumatic disease or inflammatory joint disease other than RA will be 
excluded. Subjects with any history  of use of adrenocorticotropic hormone (ACTH) for the treatment of RA ,
and subjects who have taken B -cell mediated therapies in the 24 weeks prior to screening will be excluded.
Subjects must be negative for hepatitis B, hepatitis C, and tuberculosi s.Subjects may not have any other 

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 17of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtScreening Matching placebo 2x/week for 
12 weeksActhar 1 mL (80 U) 2x/week 
for 12 weeks
Acthar 1 ml (80 U) 
2x/week for 12 weeksLDA
No
LDAFollow -up 28 ( ±2) 
days after last dose 
of study drugFollow -up 28 ( ±2) 
days after last dose 
of study drug
Screening
Day -28 to Day -1Open Label Treatment Period
Week 1 to Week 12Randomized Maintenance Period
Week 13 to Week 24Follow -up7STUDY SCHEMA TIC AND SCHEDULE OF EVENTS
7.1 Study Schematic
Figur e 7-1: Study Overview

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 18of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt7.2 Schedule of Study Events
Table 7-1: Schedule of Study Events
Assessment/Procedure
Screening
(Day-28 to Day -1)Part 1
Open Label PeriodPart 2
Randomized Maintenance Period
Unscheduled Visita
Follow-up 28 (± 2) Days After Final Dose of 
Study DrugWeek0/Base -
line4(± 5 
days)8(± 5 
days)12(± 2 
days)16(± 5 
days)20(± 5 
days)24 (± 5 days) 
/Early 
Termination
Informed Consent X
Inclusion/Exclusion Criteria Review X X
Medical/Surgical History X
Current Medical Condition Review X X X X X X X X X
Demographics X
Complete Physical Examination X X
Limited Physical Examination X X X X X X X X
28 Joint Count X X X X X X X X
Height and WeightbX X X X X X X X X X
Vital SignscX X X X X X X X X X
Clinical Laboratory TestsdX X X X X X X X X
HbA1c X X X
ESR and CRP X X X X X X X X
Serum Pregnancy Test X X
Urine Pregnancy Test X X X X X X X
Hepatitis Serology X
IGRA for TB X
X X X
 and Urine Creatinine Sample s X X X
General Health VAS X X X X X X X X
Patient Assessment of Pain (VAS) X X X X X X X
Patient Global Assessment of Disease Activity (VAS) X X X X X X X
Physician Global Assessment of Disease Activity (VAS) X X X X X X X

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 19of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtAssessment/Procedure
Screening
(Day-28 to Day -1)Part 1
Open Label PeriodPart 2
Randomized Maintenance Period
Unscheduled Visita
Follow-up 28 (± 2) Days After Final Dose of 
Study DrugWeek0/Base -
line4(± 5 
days)8(± 5 
days)12(± 2 
days)16(± 5 
days)20(± 5 
days)24 (± 5 days) 
/Early 
Termination
HAQ -DI X X X X X X X
FACIT -F X X X X X X X
WPAI X X X X X X X
Hospital Admissions, ED and Nonstudy Outpatient Visits X X X X X X
IXRS Contact X X X X X X X
Discontinue Subjects Who Have Not Achieved LDA, 
Randomize Subjects With LDAX
Study Drug and Diary Training X
Study Drug Accountability X X X X X X
Dispense Study Drug X X X X X X
Administer First DoseeX
Diary  Review X X X X X X
Adverse Events and Concomitant Treatments X
aChecked assessments are required at any unscheduled visit. Additional assessments may be done at the investigator’s discretion.
bHeight is required at screening only.
cBlood pressure, pulse rate, respiratory rate and body temperature. Blood pressure will be measured in tripl icate at the Screening and Baseline Visits
dChemistry, hematology, u rinaly sis.
eThe first dose will be a dminister edclinic and the subject will be observed for at least 1 hour after dosing.

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 20of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt8ETHICAL  CONSIDERA TIONS
This clinical s tudy is designed to comply wit h ICH Guidance on General  Consi derati ons f or 
Clinical Trials and applicable nat ional and l ocal regul ations.
8.1 Institutional Review Board /Independent Ethics Committee
It is the responsibilit y of the invest igator to obtain the app roval o f the IRB/IEC before the start 
of the study . Theinvestigator willpr ov ideM all inckrodtwithastatementofcomplia nce fro m
the IRB/IEC and/or the US Department of Healt h and Human Services general assurance 
number . A copy  of the approval  letter along with a roster of IRB /IEC members and 
compliance letter and/or the US Department of Health and Human Services general assurance 
number will be retained as part of the study  records . During the course of the study , the 
investigator will provide timely and accurate reports to the IRB /IEC on the progress of the 
study  at appropri ate intervals (not to exceed 1 year) and at the complet ion of the study . The 
investigator will notify the IRB /IEC of serious adverse events ( SAE )or other si gnificant 
safet y findin gsper IRB /IEC guidelines . The study  protocol , informed consent form (ICF), 
advert isements (if any), and amendments (if any) will be approved by the IRB /IEC in 
conformance withinternati onal,national and l ocal regul atory  requi rements; and the Code of 
Fede ral Regulati ons ( CFR ), Title 21, Part 56 (where applicable) .
8.2 Ethical Conduct of the Study
The study  will be conducted in full compliance with applicable internat ional, nat ional and 
local regulatory  requi rements; United States (US) Food and Drug Administration (FDA) 
regul ationsincluding 21 CFR 314.106 and 312.120, (where applicable );and ICH guidelines 
for good clinical pract ice (GCP )and in accordance with the ethical principles that have their 
origins in the Declaration o f Helsink i.
8.3 Subject Information and Consent
The ICF must be approved by  the sponsor and the IRB /IEC before any subject provide s
consent. The investigator will provide Mallinckrodt with a copy  of the IRB/IEC -approved ICF
and a copy  of the IRB/IEC’ s wri tten approval  before the start of the study .
At the Screening Visit , subjects will read the ICF and a Health Insurance Portabilit y and 
Accountabilit y Act  (HIP AA) authorizat ion form (if applicable) after being given an 
explan ation of the study . Bef ore si gning the ICF and the HIP AA authori zationform (if 
applicable), subject s will have an opportunit y to discuss the contents of these forms with study  
site personnel. 

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 21of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtSubjects m ust assent understanding of and vo luntarily sign the se forms in com pliance wi th 
ICH GCP guidelines and 21 CFR, Parts 50 and 312 (where applicable) , before parti cipat ing in 
any study -related procedures. Subjects will be made aware that they may wit hdraw fro m the 
study  at any  time. Subjects unable to give wri tten inform ed consent m ust orally assent to the 
procedures, and written informed consent must be obtained fro m a legally authori zed 
representative in accordance with nationaland l ocal laws, as applicable.
The ICF must contain all applicable elements of in formed consent and the mandatory  
statements as defined in by nat ional and l ocal regulat ions including confident iality.All
versionsofeachsubjec t's signed ICF m ustbekept onfilebythesitefor possible in spection by
regulatory aut ho ritiesand/or au tho riz edMallinck rodtpersonnel.Signed copi esof the ICF and 
the HIP AA authori zation form, if applicable, will be given to the subject . 
The subject s will be made aware of their right to see and copy  their records rel ated to the 
study  for as l ong as the inve stigator has possession of this information. If the subject
withdraws consent and/or HIP AA authori zation, the invest igator can no longer disclo se health 
inform ation, unless it is needed to preserve the scient ific integrity of the study .
9BACKGROUND INFORMA TION AND RA TIONALE
9.1 Overview
Rheumatoid arthrit is (RA) is an autoimmune disorder characterized by chronic inflammat ion, 
articular erosi ons,and periart icular bone los s.Proinflammatory  cytokines are the primary 
mediators of synovial inflammat ion and ensuing bone and cartilage destruction in mult iple 
joints (Arend, 2001 ; Harri s, 1990 ). Once considered simply  a disease involving the joints, it is 
now recognized as a process involving mult iple organ systems ( Lévy  et al , 2008 ; Wolfe et al, 
1994; Mutru et al , 1976 ; Isom äki et al , 1975 ).
Rheumatoid arthrit is has a significant neg ative impact on the abilit y to function in all settings, 
with increasing decline in funct ioning related to disease progression ( Pincus et al , 1984 )
, and 
is associated with increased morbidit y and m ortali ty (Wolfe et al, 1994; Wolfe et al, 2003). In 
developed countries, the prevalence of RA  has been est imated at 0.5% to 1.0% of the adult 
popul ation, wi th an annual incidence rate between 5 to 50 new cases per 100,000 ( Scott et al, 
2010).
The 2010 Amer ican Co llege o f Rheumatol ogy(ACR) /European League Against Rheumat ism 
(EULAR) updated the classificati on of RA in order to i dentify patients earlier in the disease 
so that disease m odifying ther apy could be ini tiated to sl ow disease progressi on (Aletaha et 
al, 2010 )
.Thegoaloftreatment is a treat -to-target strategy , focused on achieving remission, defined 

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 22of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtas the absence of  inflammatory disease, with achievement of low disease activity (LDA) an 
acceptable alternative therapeutic goal ( Singh et al, 2016 ; Smolen et al, 2010 ; Smolen et al, 2013 ).
The cornerstone in the manag ement of RA  is the use of disease modif ying antirheumatic drugs 
(DMARD s) which have significantly reduced or even reversed disease progression, and improved 
symptoms as well as q uality of life. Disease modifying antirheumatic drugs are often divided into 
nonbiologic and biologic agents (Singh et al, 2016 ; Smolen et al, 2010 ; Smolen et al, 2013 ).
Nonbiologic agents are drugs that have been synthesized, and include methotrexate (MTX), 
sulfasalazine, hydrochloroquine, leflunomide and most recently tofacitinib (Smolen et al, 2010 ; 
Smolen et al, 2013 ).With the excepti on of tofacitinib, the non biologic DMARDs are non specific 
drugs that disrupt the immune process; in contrast, tofacitinib is targeted at a specific immune 
pathway , namely the janus kinase (JAK) receptor ( Kyttaris, 2012 ) .Biologic agents are derived from 
living matter and target very specific genes or proteins ( Morrow and Felcone, 2004 ).In RA, a deeper 
understanding of the pathophysio logy of RA  has led to the development of mon oclonal antibodies 
and receptor decoys ( Kyttaris, 2012 ).Tumor necrosis factor -alpha (TNF -α) is an infla mmatory 
cytokine involved in RA. B lockade of  TNF -α reduces producti on of numerous proinflammatory 
cytokines ( Feldmann and Maini, 2003 )and led to the development of a number monoclonal antibody
anti-TNF agents, including etanercept, adalimumab, infliximab, certolizumab and golimumab ( Singh 
et al, 2016 ; Arend, 2002 ).Otherbiologic targets include proinflammatory cytokines ( interleukin -1 
andinterleukin -6 [anakinra and tocilizumab, respectively ]), the co stimulatory signal for T-cell 
activation (abatacept), and the CD20 receptor on B-cells (rituximab) ( Arend, 2002 ; Nishimoto et al, 
2008 ; Buch et al, 2009 ; Taylor and Lindorfer , 2007 ). 
Methotrexate is considered to be the first -line DMARD of  choice.When there is persistent disease 
activity the next step is use of MTX in combination with other nonbiologic s such as leflunomide, or 
initiation of a biologic DMARD, with or without concomitant MTX , and considerati on of low dose 
corticosteroids ( Rath and Rubbert, 2010 ; Singh et al, 2016 ; Smolen et al, 2010 ; Smolen et al, 201 3).
Despite significant adva ncesin the treatment armamentarium for RA, 28 %to58% patients do n’t 
achieve even a minimal 20% improvement in ACR (ACR20 ) criteria (Redlich et al, 2003 ), and those 
that do achieve improvement can have a waning of treatment response ( Finckh et al, 2006 ), 
demonstrating continued unmet need in the management of RA.
Corticosteroids are powerful immu ne suppressants, and have a significant impact on the immune 
system through multiple mechanisms inc luding inhibition of proinflammatory cytokine producti on, 
inhibit ion of macrophage activation, and disrupti on of T -cell activity ( Townsend and Saag, 2004 ).
Dysfunction of the hypothalamic -pituit ary-adrenal axis may have a r ole in the onset and continued 
presence of chronic inflammation in RA  as evidenced by the observation that patients with RA  have 
lower cortisol levels compared to healthy controls ( Im rich and Rovensk ý, 2010 ). Corticosteroids 
have been shown to have benefit in RA, with reducti on in inflammation as well as reducti on in 

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 23of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtdisease progression ( Graudal and Jürgens, 2010 ; Bijlsma et al, 2003 ; Kirwin, 1995 ), although the 
results are sometimes contradictory , especially in early RA  (Capell et al, 2004 ) .The use of 
corticosteroids is typically limited by adverse events (AE) , including impaired glucose metabolism 
and frank diabetes, hypertension, osteoporosis, osteonecrosis, peptic ulcer disease, mood and 
behavioral effects, weight gain, increased risk of serious infections ( Bijlsma et al, 2003 ), which has 
prom ulgated recommendations for limitations on dose and use of these agents in the management of 
RA (Bijlsma et al, 2003 ; Singh et al, 2016 ; Smolen et al, 2013 ) .Addit ionally , up to 30% of pat ients 
are thought to be resistant to corticosteroids ( Chikanza and Kozaci, 2004 ; Silverman and 
Sternberg, 2008 ), which further limits the potential benefit of this drug class.
As described in the Prescribing Informat ion, Acthar Gel (reposi tory corticotrop hin
inject ion, hereafter referred to as Acthar) contains ahighly purified porcineadrenocorti cotropi c
horm one (ACTH) analogue ( Mallinckrodt ARD, 2015). A CTH is a memb er of the fam il yof
structurallyrelatedpeptides knownasmelanoco rtinpeptides.Melanocor tinpeptides,which in
add
itiontoACTH include α-, β-, a ndγ -melanoc ytestimulating horm ones, arederived fro m the
natural prote inpro-opiomel anoco rtinand exert their physio logic effects by  binding tocell
surfaceG-prote incoupled r ece ptors knownasmelanoco rtin recept ors(MCR ),activat ion of the 
JAK-signal transducer and inhibi tion of nuclear factor -B(Buggy , 1998 ; Mountj oy et al , 
1992) . Five subtyp es of MCRs havebeen identifiedtodate(MC1 R-MC5 R),each with different
tissuedistributions,bindingaffinitycharacteristic s,and ph ysiological roles(Getting, 2006 ).
ACT
Hbinds to all 5 subtypesofMCR (Schioth et al , 1995 )andrecent experiments
de
monstra te that Acth aralsohasagoni s t activityfor all 5 MCRs(Mallinckrodt, Unpublished 
Data ).
From  a mechanist ic standpoint, Acthar has several potential pathways that may play a role in 
the effects in RA. ACTH has steroidogenic properties, which are exclusively mediated b y 
MC2R ( Cooray and Clark, 2011 );as previously noted, corticosteroids are potent 
immunosuppressants ( Bijlsma et al, 2003 ; Graudal and Jürgens, 2010 ; Kirwin, 1995 ;Townsend and 
Saag, 2004 ). However, there are other potential nonsteroidogenic targets that could impact 
immune regulation and inflammation. Activation of MC1R affects the Nuclear Factor -ƙB
pathway leading to down regulation of proinflammatory cytokines and chemokines ( Ahmed et 
al, 2013 ).  MC1R, MC3R and MC5R are expressed by multip le cells in the immune system 
(Ahmed et al, 2013 ; Cooray and Clark, 2011 ; Starowicz and Przewlocka, 2003 ), and MC1R
and MC5R are present in the human articular chrondrocytes and rheumatoid synovial 
fibroblasts (Ahmed et al, 2013 ).MC2Rand MC4R are also expressed on human articular 
chondrocytes .MCRs are also expressed on osteoclasts and osteoblasts 
(Patel et al, 2010 ). 
An evaluat ion of the effect of Acthar and etanercept in a co llage n-induced arthrit is (CIA) 
animal modeladministered al oneand in co mbination was conducted. Overall efficacy of 

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 24of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtcorticotropin and etanercept used alone in established CIA  were com parable, however 
corticotropin in co mbinat ion with etanercept synergist ically attenuated anti -collagen 
antibodies and both clinical and histopathologic measures of CIA  vs etanercept alone (Decker 
et al, 2015 ).Further, the combinat ion of Acthar and etanercept resulted in significant 
attenuation of CIA -induced reducti ons in average bone densit y, an effect that was not seen in 
either treatm ent when administered alone ( Decker et al , 2015). 
Clinical effects of ACTH in RA  have been reported since the 1950’ s (Clark et al, 1953 ; Hench 
et al, 1950 ; Levin et al, 1953 ; Maso n, 1953 ; Savage et al, 1959 ; Solem and Römcke, 1955 ).  
Preliminary results of an open label evaluat ion of Acthar in the treatment of subjects with RA  
who had not adequately responded to current b io
logic DMARD therapy and who had a history 
of inadequate response to at least 2 other biologic agents with different modes of action 
suggested positive response in Disease Act ivity Score in 28 J ointserythrocyte sedimentation 
rate (DAS28 -ESR)when subjects were dosed for 12 weeks with Acthar 80 units (U)every 72 
hours ( Gillis et al, 2015 ).Preliminary data from another study evaluating the effect of Acthar
(dosed as 80 U weekly or 80 U twice weekly )in combination wit h MTX in newly diagnosed 
RA subjects reported interim results in 10 subjects suggesting improvement in the Clinical 
Disease Activity Index (CDAI) for the majority of subjects, with half of the subjects achieving 
at least LDA  as well as regression of osteitis, synovit is,and erosi ons in some pati ents (Gaylis 
et al, 2015 ).Addit ionally , a retrospective case series evaluatedthe adj unctive use of Acthar in 
5 patients wi th RA that was refractory  to 2 to 5 DM ARDs , described improvement in 
inflammatory  biomarkers and reported symptoms (Brown, 2015 ). 
The current study  seeks  the efficacy o f Act har in the management of RA  in pat ients 
who have persistent disease act ivity, with secondary evaluat ion of potential benefit after LDA  
is achieved.
9.2 Product Description
 
 
 
 
Acthar is currently approved as adj unctive therapy (to t ide the patient over 
in acute episode or exacerbat ion) in: Psoriat ic arthrit is, including juvenile RA  (selected cases 
may require low dose maintenance therapy ), ankylosing spondylit is (Mallinckrodt ARD, 
2015 ).

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 25of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtPlacebo i s a sterile preparat ion of 16% gelatin for intramuscular or SC inject ion.  
 
 Placebo form ulation is i dentical to Acthar except that it 
contains no active medicat ion
9.3 Dosage and Administration
Invest igational medicinal product (IMP) or s tudy drug will be used to denote active drug 
(Acthar) and/or matching placebo .
Following a screening period of up to 28 day s, subjects wi th RAwith persistent ly act ive 
disease will  receive open label treatment with 1 mL  (80 U) of ActharSC 2x/week for 12 
weeks in  Part 1 (Open Label Period) of the study .
After 12 weeks of treatment with Acthar, subjects will be evaluated for treatment resp onse 
using the DAS28 -ESR. Subjects who have achieved LDA , defined as DAS28 -ESR < 3.2 ,
will enter a double -blind rando mized maintenance period ( Part 2, Randomized Maintenance 
Period) and receive either Acthar 1 mL (80 U) SCormatching placebo SC2x/week for an 
additional 12 weeks. Subjects who do not achieve LDA  will be discont inued fro m study  
participat ion.
9.4 Rationale
Thedoses for this study  were chosen based on safety  and informed by prescribing patterns for 
RA.
Current sm all open label  studi es evaluat ing treatment refractory  RA and newly diagnosed RA  
have a dosing strategy  that ranges fro m Act har 80 U weekly to 80 U every  72 hours ( Gillis et 
al, 2015 ; Gaylis et al, 2015 )
.
The prescribing i nformat ion for Acthar recommends the use of 40 to 80U administered 
intramuscularly  or SC every  24 to 72 hours in adults and children over 2 y ears of age; the 
specific dose is individualized according to the medical condit ion (Mallinckrodt ARD, 2015 ). 
The recommended dose is daily intramuscular or SC doses of 80 to 120 U for 2 to 3 weeks for 
acute exacerbations. Recently published data suggests that based on serum  cortisol-equivalent 
exposure (assuming lineari ty), 80 U of Acthar equates to 30 mg of intravenous 
methylpredniso lone (Lal et al , 2015 ) . 

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 26of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt9.5 Risk/Benefit
Themost comm on adverse react ions for Acthar are similar to those of corticosteroids and 
include fluid retention, altera tion in glucose tol erance, elevat ion of blood pressure, behavioral
and mood changes, and increased appet ite and weight gain. Acthar is also associated with 
increased susceptibilit y to new infect ion and increased risk of exacerbation, disseminat ion, or 
reactivation oflatent infect ions(Mallinckrodt ARD, 2015).
Rheumatoid arthrit is is a disorder characterized by  progressive bone and cartilage damage, 
with impact on other organ systems ( Arend, 2001 ; Lévy  et al , 2008 ;Harri s, 1990 ; Wolfe et al, 
1994), and is associated with substant ial morbidity and m ortali ty (Wolfe et al , 1994; Wolfe et 
al, 2003 )
. Treatment guidelines for RA  state that the treatment target is complete remissio n or 
LDA  (Singh et al, 2016 ; Smolen et al , 2013 ) .Current therapies are inefficacious in up to 58% 
patients (Redlich et al, 2003 ).  
 
10OBJECTIVES
10.1 Primar y Objective
The primary objectiveof this study  is:
Toassess the efficacy o f Acthar given as a1 mL  (80 U) dose 2x/week for 12 weeks as 
determined by DAS28 -ESR in subjects with RA with persistent ly active disease .
10.2 Secondary Objective s
The secondary  objectives of this study  are:
To assess the safet y and tol erabili ty of Acthar in subjects with RA  with persistent ly 
active disease.
To assess the efficacy o f Act har in maintaining LDA in subjects wi th RA with 
persistently act ive disease who have achieved LDA  after 12 weeks o f treatm ent.
10.3 Exploratory Objective s
An e xploratory  object ivesof this study  are:
  
 

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 27of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt11STUDY DESIGN
11.1 Description
This is a mult icenter, mult iple dose study  to examine the effect of Acthar in adult subjects 
with RA with persistently act ive disease . Approximately 232subjects will be enrolled.
During the first part of the study (Part 1 -Open Label Period) all enrolled subjects will be 
treated with Acthar 1 mL  (80 U) SC 2x/week for 12
weeks to assess the proportion of subjects 
who achieve LDA.
After 12 weeks of Acthar treatm ent, subj ects who have achieved LDA (define d as DAS28 -
ESR < 3.2) will enter a double -blind rando mized maintenance period ( Part 2 -Rando mized 
Maintenance Period) and wi ll be rando mized in a 1:1 ratio into 2 groups:
Group 1: Acthar 1 mL (80 U) SC 2x/week for an addit ional 12 weeks .
Group 2: Placebo 1 mLSC 2x/week for an addit ional 12 weeks .
Subjects who do not achieve LDA  at W eek 12 will be discont inued fro m the study .
Subjects who experience a flare in disease act ivitywill be discont inued fro m the study . Flare 
or worsening o f disease act ivity is def ined as:
Weeks 0 to 11:DAS28 -ESR ≥ 3.2 and increase of 0.6 fro m the Week 0 assessment
sustained over 2 consecutive study  visits; or DAS28- ESR ≥ 3.2 and increased of 1
from the Week 0 assessment at a single visit.
Weeks 13 to 23:DAS28 -ESR < 3.2 and increase of 1.2 from the W eek 12 assessment;
or
 DAS28 -ESR ≥ 3.2 and increased of 0.6 from the W eek 12 assessment sustained
over 2 consecut ive study  visit s;or DAS28 -ESR ≥ 3.2 and increase o f 1 fro m the
Week 12 assessment at a single visit (van der Maas, 2013 ).
All subjects will have a Follow-up V isit 28(±2)days after thei r last dose of study  drug.
11.2 Approximate Duration of Subject Participation
Subject swill part icipate in the study  for a total  of up to approximately 32weeks , incl uding a 
screening period of  up to 28 day s
,and active treatment period of 24weeks ,and a fo llow-up 
visit of 28 (±2) days after last dose of study  drug . 

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 28of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt11.3 Approximate Duration of Study
The durati on of  the study  from first subjec tfirstvisit to last subject last visit will be depen dent 
on the abilit y of the si tes to i dentify and enroll eligible subject s. The ent ire study  is expected 
to require approximately 4 .5years to com plete.
11.4 Approximate Number of Subject s
It is expected that approximately 360 subjects will be screened and 232 subject swill be 
enrolledatapproximately 100sitesglobally.
12SELECTION OF SUBJECT S
12.1 Inclusion Criteria
Subject smust meet all of the fo llowing cri teria for inclusio n in the study  at the Screening 
Visitandthe Baseline Visit .
1.Subject s must be adequately  informed and understand the nature and risks of the study  and
must be able to provide a signature and date on the ICF.
2.Subjects m ustbe ≥ 18 y earsofageat Screening V isit and can be male or female.
3. Female subjects must be of nonchildbearing potential (hi storyofhystere c tomy,bilateral
oophorectomy, or postme nopaus alwithnohistoryofm e nstrual flow inthe 12 mon ths prior
to
the Screening Visit), or if o f childbearing potential must be nonpregnant, nonlactating
and agree to use effect ive contraception with a male partner throughout study  parti cipat ion
(through the Follow -up V isit).Acceptable forms of contraception include hormonal
measures (oral contraceptive pills, contraceptive patch, contraceptive ring, injections),
intrauterine device s,doubl e barri er method (condom plus diaphragm, condom  or
diaphragm  plus spermicidal gel or foam) ,and abstinence.
4.Male subjects with a female partner of childbearing potential must have been surgically
sterilized (vasectomy) or agree to use a double barrier method for contraception (condom
plusdiaphragm , condom  or di aphragm plus spermicidal gel or foam) or rem ain abst inent
throughout their study  participati on (through the Follow -up V isit).
5.Subjects must meet the criteria for RA  as defined by the 2010 ACR /EULAR classification at
the Screening V isit(Aletaha et al, 2010 ).
6.Subjects must have persistently active RA  defined as a DAS28 -ESR 3.2 despite treatment
with required biologic/nonbi ologic DMARD (
s)and a corti costeroid as defined below at the
Screening and Baseline V isits.

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 29of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt7.Subjects must have been on a corticosteroid in the 12 weeks pr ior to the S creening Visit and
on a stable dose of  5mg to 10 mg of prednisone (or prednisone equivalent) f or 4 weeks pri or
to the Screening Visit.
8.Subjects must have been on 1 of the f ollowing:
MTX ≤ 20 mg per week and 1 addi tional allowed biol ogic or nonbi ologic DMARD f or at
least 12 weeks prior to the Screening V isit and must remain on thosedosesthroughout
the study , OR
One allowed bi ologic DMARD f or at least 12 weeks pri or to the Screening V isit and
must remain on that dose throughout the study .
Table 1 2-1          Allowed DMARDs
Allowed Nonbiologic DMARDs Allowed Biologic DMARDs
Sulfasalazine 2 to 3 g per day (QD) Infliximab 3 to 10 mg/kg every 4 to 8 weeks
Leflunomide 20 mg QD Adalimumab 40 mg every other week
Hydroxychloroquine (HDQ )up to 200 mg twice a 
dayEntanercept 50 mg per week
Tofacitinib 10 mg QD Certolizumab 200 mg per week to 400 mg ever y 4 
weeks (inclusive)
Golimumab 50 mg per month
Abatacept 125 mg/mL SCper week or 500 to 1,000 
mg intravenously every  4 weeks
9.Subjects taking non -steroidal ant i-inflammatory drugs must be on a stable dose for 4 weeks
prior to the Screening Visit, and remain on a stable dose throughout study participat ion.
10.Subjects m ust have a mean systolic blo od pressure≤ 140 mm Hgand a di astolic blood
pressure of
 ≤ 90 mm Hg determ ined by the average of3 seated readings taken atleas t 5
minutesapart atthe Screening and Baseline Visits.
11.Subject s must be able to communicate effect ively with study  personnel.
12.Subject s must be able and willing to fo llow all protocol requirements and study
restri ctions.
13.Subject s must be able and willing to return for all studyvisits.

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 30of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt12.2 Exclusion Criteria
Subject s are ineligible for study  participat ion if they meet any  of the f ollowing cri teria at the 
Screening Visit and/or the Baseline Visit as outlined below:
1.Subject is from a vulnerable populat ion, as defined by  the US CFR Title 45, Part 46,
Secti on 46.1 11(b) and other local and nat ional regul ations, including but not limited to ,
employees (tem porary , part -time, full t ime, etc) or a family member of the research staf f
conducting the study , or of the sponsor , or of the clinical research organizat ion, or of the
IRB/I EC.
2.Subject has taken any  investi gational treatm ent for RA  or any  biologic invest igational
agent in the 24 weeks prior to the first dose of study  drug or an y nonbio logic
investigat ional agent within6 weeks prior to the first dose of study  drug .
3.Subject is unwilling to receive ,orisintolerant of ,SCinject ions.
4.Subject has any history  of use o f ACTH preparations for treatment of RA(including but
not limite d to Acthar and Synacthen®).
5.Subject has a history  ofsensi tivity to ACTH preparations (including but not limited to
Acthar and Synacthen) .
6.Subject has a history  ofsensi tivity to porcine protein products.
7.Subject has any current rheumatic autoimmune disea se other than RA.
8.Subject has current inflammat ory joint disease other than RA.
9.Subject has used B -cell mediate dtherapi es (including, but not limited to rituximab) in the
24 weeks prior to the Screening Visit or will use such treatments during the study.
10.Subject has used intraarticular corticosteroids in the 14 days prior to the Screening V isit.
11.Subject has any  known contraindicat ion(s)to Acthar ( Mallinckrodt ARD, 2015 )including,
but not limited to:
Any known history  of scler oderm a, osteoporosis, or ocular herpes simplex.
Any current uncontrolled hypertensio n, primary  adrenocorti cal insufficiency , or adrenal
cortical hyperf unction.
Any current congestive heart failure ( defined as New Y ork Heart Associat ion
Funct ional Class III to IV).
Pepti c ulcer (wi thin24 weeks prior to the Screening V isit).
Recent ma
jor surgery  (within24 weeks prior to the Screening Visit )

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 31of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt12.Subject has a history  of chronic active hepat itis including active or chronic hepat itis B, or
acute or chronic hepat itis C.
13.Subject has a h istory  of tubercul osis (TB) infect ion, any signs/symptoms of activeTB,or
any close contact with an individual wit h an active TB infect ion
.
14.Subject has had a clinically significant infect ion requiring intravenous administration o f
antibiotics and hospitalizat ion in the 4 weeks prior to the Screening Visit .
15.Subject has k nown immune co mpromised status, including but not limited to ,individuals
who have undergone organ transplantation or who are known to be positive for the human
immunodeficiency  virus .
16.Subject has Type 1 or T ype 2 diabetes mellitus (prior diagnosis of gestational diabetes
mellitus is not exclusion ary)or is current ly taking hypoglycemic medicat ions.
17.Subject has any  solidtumormalignanc ycurrent ly diag nos edorundergoingtherapy,orhas
received therapy forany solidtumormalignancy inthe 5 y earspriorto the Screening Visit,
withtheexceptionoftreatedandcured bas a l ce llcarcinoma,treated andcuredsquamous
cellcarcinomaofthe skin, andtreatedandcur ed carci noma in situof thec erv ix.
18.Subject has a diagnosis of , isundergoingtherapy for, orhas recei vedthera pyfor a
hematologicmalig nancy inthe 5yearspriortothe ScreeningVisit.
19.Subject has current or recent (within 24 weeks prior to the Screening Visit) drug or alcohol
abuse as defined in Diagnost ic and Statist ical Manual of Mental Disorders , Fifth Edit ion,
Diagnostic Cri teria for Drug and Alcoho l Abu se(American Psychiatri cAssociat ion,
2013 ).
20. Subject has a ny of the following laboratory  abnormali tiesat the Screening V isit:
Hem oglobin ≤ 8.0 g/dL .
Platelets≤ 50,000 cells/ μL.
Absolute neutrophil count ( ANC ) ≤ 1000 cells/ μL.
Aspartate aminotransferase (AST ), alanine aminotransferase (ALT), or t otal bilirubin
2 times upper limit of normal ( ULN ).
Glycosylated hemoglobin (HbA1c) 6.5%.
Positive Hepat itis B surface ant igen (HBsAg) or Hepatit is B core antibody (HBcAb) .
Positive Hepat itis C virus ant ibody  (HCV) andHCV polymerase chain reaction (PCR)
≥ 25 IU/mL (HCV PCR will be automat ically analyzed if HCV is posit ive).
Positive or indeterminate interferon gamma release assay (IGRA).

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 32of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt21.Subject has any other clinically significant disease ,disorder or laboratory  abnorm ality
(including those listed on the Prescribing Informat ion Section 5: W arnings and
Precauti ons [Mallinckrodt ARD, 2015 ]) which, in the opinion o f the invest igator (by  its
nature or by  being inadequately controlled), might put the patient at risk due to
participation in the study , or m ay influence the results of the study  or the subject ’s abilit y
to com plete the study .
12.3 Screen Failure
Subjects wi ll bea llowed torepeatanysingle screeningassessment/ procedureonce , if ne cessary ,
ifit iswithinthe screening window. The subject will not be considered a screen failure unless 
the repeat assessment/procedure resul ts donot meet eligibilit y criteria. The peri od from starting 
screening related procedures at the Scree ning Visit to the Baseline Vis itmust not exceed 28
days, inclusive of any  repeat screening procedures .
Subjects who do not meet all o f the eligibilit y criteria at the Screening or Baseline V isits will 
be deemed a screen failure and the reason for the screen failure will be documented. A subject 
who is ascreen failure at the Screening or Baseline Visit may be re screened. The subject must 
repeat all screening procedures. The period fro m the start of re screening related procedures to 
the first dose of study  drug must not exceed 28days. Subjects may be rescreened only once.
13PRIOR AND CONCOMIT ANT MEDICA TION/NONDRUG THERAPIES
The start and stop date, dose, unit, frequency , route of administration, and indicat ion for all 
prior(taken within the 30 days prior to thefirst dose of study  drug) and concomitant
medicat ions and nondrug therapies (eg, bl ood transfusio ns, oxy gen supplementati on) received
will be recorded .
In addit ion, all prior treatm ents for RAwill be recorded with start and stop date, dose, unit, 
frequency  and route of administra tion.
In addit ion, opi oid use for pain management is allo wed during the study , however, it cannot be 
used in the 48 hours prior to each study  visit. Non -steroi dal ant i-inflammatory  drugs for pain 
management are allowed during the study , however, subjects m ust have been on the 
medicat ion for at least 4 weeks pri or to the Screening V isit and remain on a stable throughout 
the study .
13.1 Prohibited Concomitant Medications /Nondrug Therapies
The fo llowing medications/ nondrug therapies will not be permitted during the study :
Intraarticular corticosteroids.

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 33of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtLive or live -attenuated vaccines.
Enteral or parenteral immunosuppressive medicat ions including ,but not limited to
azathioprine, cy clophosphamide, cy closporine, tacrolimus, mycopheno lare mo fetil,
rituximab (or other B -cell inhibitors) .
Any invest igational drug, device, or procedure administered as part of a research study .
If any prohibited medicat ion is taken during the study , all pertinent information will be 
recorded in source documents and the electroni c case report form ( eCRF ). The designated 
study  medical monitor ( MM) must be informed immediately so the sponsor may determine 
whether to continue the subject in the study .
14PROCEDURES /ASSESSMENTS
Theschedule of study  procedures issummarized in the Schedule of Study  Events (Table 7 -1).
14.1 Screening Visit (Study Days -
28to -1)Procedures /Assessm ents
Screening assess mentsmustbeperfor medwithin 1to 28days prior to the Baseline Visit . 
Thefollowing procedures willbe perfor medattheScreening Visit :
Inform ed consent.
Inclusio n/exclusio n criteria.
General Healt h Visual Analog Scale (VAS).
Medical and surgical history .
Demographics .
Com plete p hysical examinat ion.
28 Joint Coun t.
Height and Weight.
Vital signs .
Clinical laboratory  tests .
HbA1c .
ESR and C -reactive protein ( CRP ).
Serum  pregnancy test .
Hepati tis serol ogy.

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 34of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtIGRA  test for TB.
Contact the Interactive Phone/W eb Response System (IXRS) and confirm disease 
activit y.
Adverse event sand conco mitant medicat ions.
Subjects will be allowed to repeat any  screening procedure once , if necessary , if it is within 
the screening window .
14.2 Baseline V isit(Week 0)andFirst DoseProcedures /Assessm ents
Predose evaluat ions will occur prior to the first dose of study  drug .
The invest igator or designee will co mplete the fo llowing procedures predose : 
Inclusio n/exclusio n criteria review ; subject must meet all eligibilit y criteria at
screening and baseline
.
Efficacy Questionnaires: General Healt h (VAS), Patient Assessment of Pain (V AS), 
Patient Gl obal Assessment of Disease Act ivity (VAS), Patient Assessment of Physical 
Funct ion assessed using the Health Assessment Questionnaire -Disabilit y Index 
[HAQ -DI]), Functional Assessment of Chronic Illness Therapy- Fatigue Scale 
(FACIT -F) and Physician Glo bal Assessment of Disease Activit y (VAS).
Work Productivit y and Act ivities Impairment (WP AI).
Current medical condit ionreview .
Limited physical examinat ion.
28 Joint Coun t.
Weight.
Vital signs .
Clinical laboratory  tests .
ESR and C RP.
Urine pregnancy  test.
Vectra Disease Activit y (Vectra®DA) sample .

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 35of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtSerum  and urine samples for  
 
 
 and urine creat inine.
Subject diary  training.
Contact IXRS and confirm disease act ivity eligibili ty.
Dispense study  drug kits.
Study  drug administration under supervisio n of study  staffand observat ion for at least 
1 hour thereafter . Administration of all other doses will be done at home by the 
subject/caregiver .
Adverse event sand conco mitant medicat ions.
14.3 Week 4 (± 5 days) and8(± 5 days) Procedures /Assessm ents
Efficacy Questionnaires.
WPAI.
Current medical condit ionreview .
Limited physical examinat ion.
28 Joint Coun t.
Weight.
Vital signs .
Clinical laboratory  tests . 
ESR and C RP.
Urine pregnancy  test.
Hospital admissio ns, emergency depart ment (ED) visit s, and nonstudy  outpati ent 
visits.
Subject diary  review .
Study  drug accountabilit y.
Contact IXRS and confirm disease act ivity eligibili ty.
Dispense study  drug kits.

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 36of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtAdverse events and conco mitant medicat ions.
14.4 Week 12 (± 2 days) Procedures /Assessm ents
Efficacy Questionnaires.
WPAI. 
Current medical condit ionreview .
Limited physical examinat ion.
28 Joint Coun t.
Weight.
Vital signs .
Clinical laboratory  tests . 
HbA1c.
ESR and C RP.
 .
 /urine creat inine sample s.
Urine pregnancy  test.
Hospital admissio ns, ED visi ts, and nonstudy  outpati ent visi ts.
Subject diary  review .
Study  drug accountabilit y.
Contact IXRS and confirm disease act ivity eligibili ty.
Dispense study  drug kits(if appropriate) .
Adverse events and conco mitant medicat ions.
14.5 Week 1 6(± 5 days) and 20 (± 5 days) Procedures /Assessm ents
Efficacy Qu estionnai res.
WPAI.
Current medical condit ionreview .
Limited physical examinat ion.
28 Joint Coun t.
Weight.

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 37of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtVital signs .
Clinical laboratory  tests . 
ESR and CRP .
Urine pregnancy  test.
Hospital admissio ns, ED visits, and nonstudy  outpati ent visi ts.
Subject diary  review .
Study  drug accountabilit y.
Contact IXRS and confirm disease act ivity eligibili ty.
Dispense study  drug kits. 
Adverse events and conco mitant medicat ions.
14.6 Week 24 (± 5 days) /Early T ermination Procedures /Assessm ents
Efficacy Questionnai res.
WPAI.
Current medical condit ionreview .
Com plete physical examinat ion.
28 Joint Coun t.
Weight.
Vital signs .
Clinical laboratory  tests . 
HbA1c.
ESR and C RP.

/urine creat inine sample s.
Serum pregnancy test.
Hospital admissi ons, ED visi ts, and nonstudy  outpati ent visi ts.
Subject diary  review .
Study  drug accountabilit y.

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 38of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtAdverse events and conco mitant medicat ions.
14.7 Follow -up V isitProcedures /Assessm ents
The fo llowing procedures will be completed at the follow-up visit 28 (± 2) day s after the final 
dose of study  drug :
Current medical condit ion review .
Limited physical examinat ion.
Weight.
Vital signs .
Clinical laboratory  tests .
Urine pregnancy  t est.
Adverse events and conco mitant medicat ions.
14.8 Unscheduled Visit Procedures /Assessm ents
Any time that an unscheduled visit is needed to assess the subject for the study  (for exam ple, 
for an adverse event), the fo llowing minimum evaluati onsmust be completed:
Current medical condit ion review .
Limited physical examinat ion.
Weight.
Vital signs .
Adverse events and conco mitant medicat ions.
15INVESTIGA TIONAL  MEDICINAL  PRODUCT (Study Drug)
15.1 Methods of Assigning Subject s to T reatment Groups
The invest igator or designee will contact IXRS to register subjects at screening . The subject’ s 
ident ificat ion(ID) number will be determined by the IXRS and will be used to ident ify the 
subject sfor the durati on of  the study  within all  system s and docum entati on. Subject 
ident ificat ion numbers will consist of 7digits:  

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 39of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtA subject ID number will not be assigned to more than 1 subject. If a subject is not eligible to 
receive treatment, or should a subject discont inue from  the study , the s ubject ID number 
cannot be reassigned to another subject.
In the event that a subject is rescreened wit hin the screening window , they  do not need a new 
subject ID number .AtBaseline, qualified subjects who meet all of theeligibilit y criteria will 
be enrolled into the study .
The invest igator or designee must contact the IXRS to report subjects as a screen failure if the
subject does not meet eligibilit y criteria predose .
The invest igator or designee must contact IXRS to r ecord each subject visit, to receive the 
study  drug kit assi gnment s, and to report any  subject status changes .At visits where it is 
requi red, c omponents of the DAS28 -ESR (swollen jo int count, tender jo int count, ESR, 
General Healt h VAS) will be entered at into IXRS and the DAS28 -ESR will be calculated .
The invest igator must maintain a subject master log linking the subject IDto the subject ’s 
name. The invest igator must fo llow all  applicable privacy  laws in order to protect a subject ’s 
privacy  and confiden tiality. Inform ation that could ident ify a subject will be masked on 
materi al received by the sponsor .
15.2 Emergency Identification of Investigational Medicinal Product
In case of an emergency during the Rando mized Maintenance Period, when knowledge of the 
investigational product assignment is required for the medical management of an individual 
subject , the investigator may obtain the treatment assignment of the subject experiencing the 
emergency . The treatment blind for that subject may be broken by accessing the I XRS using 
instructi onsprovi ded.The investigator must notify the sponsor ’s MM or phy sician desi gnee 
immediately  after determining that it is necessary  to unblind the treatm ent assignment. The 
investigator and sponsor shoul d make every  effort to document and limit the people who are 
unblinded to the subject ’s treatm ent assi gnment. The invest igator must also indicate in source 
docum ents and in the eCRF that the blind was broken and provide the date, time, and reason 
for break ing the blind. 
15.3 Dosing Procedures
The fo llowing treatm ents will  be administered:
Weeks 0 to 12: Acthar 1 mL ( 80 U )SC 2x/week.
Weeks 13 to 24: Acthar 1 mL ( 80 U )SC 2x/pe r week ORPlacebo 1 mL SC 2x/week.

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 40of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtThroughout the trial, study drug cannot be taken on 2 consecut ivedays and cannot be taken 
more than 3 days apart.    
Both Acthar and the placebo are supplied as 5 mL  multidose vial s. Acthar vials contain 80U of 
ACTH per mL. The vial sshoul d not be over pressurized prior to wi thdrawing the product. The 
vials s hould be warmed to room temperature before using and will be labeled according to all 
applicable national and l ocal regul ations.
The subject or subject’s caregiver will administer the first dose of Acthar in the clinic under 
the supervisio n of study  staff.The subject will remain in the clinic for at least 1 hour postdose 
to monitor for allerg ic or anaphylact ic react ions.Thereafter, all doses will be administered by 
the subject or the s ubject’ s caregiver at hom e.
15.3.1 Treatment Discontinuation
Treatm ent wi th study  drug shoul d be di scontinued if any of the fo llowing occur:
Development of accelerated hy pertensi on (defined as systolic blood pressure ≥ 180 and
diastolic blood pressure ≥ 100 mm Hg) that cannot be managed by the adjustment of 
concomitant medicat ions such as antihypertensive medicat ions.
Development of congestive heart failure that cannot be managed by the adjustment of 
concomitant medicat ions such as diuretics and ant ihypertensive medicat ions.
Development of diabetic signs/symptoms (ie, HbA1c > 6.5%, or fast ing plasma glucose 
> 126 m g/dL, or cl assic symptom s of hyperglycemia with rando m plasma gl ucose 
>200 m g/dL) that cannot be managed by the adjustment of conco mitant m edicat ions 
such as insulin and oral hypo glycemic agents.
Flare or worsening of disease activit y,defined as:
oWeeks 0 to 11:DAS28 -ESR ≥ 3.2 and increase of 0.6 fro m the Week 0 
assessment sustained over 2 consecut ive study  visits; or
 DAS28 -ESR ≥ 3.2 and 
increased of 1 from the W eek 0 assessm ent at a single visit.
oWeeks 13 to 23:DAS28 -ESR < 3.2 and increase of 1.2 from the W eek 12 
assessment; or DAS28
-ESR ≥ 3.2 and increased of 0.6 fro m the Week 12 
assessment sustained over 2 consecut ive study  visits; or DAS28 -ESR ≥ 3.2 and 
increase of 1from the W eek 12 assessment at a single visit .
Failure to achieve LDA  at W eek 12.

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 41of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtDevelopment of any other AE of at least moderate intensit y and possibly , probably or 
definitely  related to study  drug that cannot be managed by the adjust ment of 
concomitant medicat ions.
15.4 Storage of Clinical Supplies
Acthar and placebo will be m aintained in a temperature controlled , secure locked area wi th 
restri cted access at the study  site.
Study  drug will be supplied in kits containing the appropriate amount of vials according to the 
treatm ent group to whi ch the s ubject i s assigned. Study  drug will be stored under refrigeration 
between 2° to 8°C (36° to 46°F). Please refer to the Pharmacy Manual for comple te 
inform ation regarding storage and accountabilit y of study  drug .
15.5 Drug Accountability
In accordance with ICH requi rements, the invest igatorwill, at all t imes, be able to account for 
all study  drug furnished to the study  site. A drug accountabilit y record will be maintained for 
this purpose. The invest igator must maintain accurate records indicating dates and quant ity of 
study  drug received, to whom it was dispensed ( subject -by-subject accounting) and accounts 
of any study  drug accidentally or deliberately  destroy ed. All unused study  drug not invo lved 
in immediate subject dosing will be maintained under locked , tem perature -controlled storage 
at the study  site. 
15.6 Compliance Monitoring
Prior to beginning the administration of study drug, subjects and/or their caregiver will be 
trained on dosing administration and m ust exhibi t proper technique. Subjects and/or their 
caregiver will be trained on the complet ion of the study  diary and will completestudy  diary 
entries to record all study drug administration and will bring it ,along wit h all study  drug kits 
including used vials to each visit. Each time study  drug is dispensed co mpliance will be 
encouraged. Subject diary training is an ongoing process as the diary will be reviewed wi th 
thesubject at each visit to monitor compliance with study  drug administration.
16SAFETY ASSESSMENTS AND PROCEDURES
The fo llowing safety  assessments will be evaluated: AEs, physical examinat ions, clinical 
laboratory  test resul ts (chemistry , hematol ogy
, HbA1c, urinalysis ,hepat it isserology, IGRA
for TB test), and vital signs .All safet y assessments will be performed at times outline din the 
Schedule of Study  Events (Table7-1). Additional (unscheduled) safety assessments may be 
perform ed as needed.

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 42of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt16.1 Adverse Events
Adverse events will be recorded from signing o f the ICF and followed by  the invest igator
until the AE is reso lved or stabilized .Any and all safet y measures (which includes standard of 
care activit ies) should be provided by the study  site to the subject .Any study  site follow-up 
shoul d be docum ented.
Refer to Section 21for addi tional details on the handling of AEs and SAEs .
16.2 Medical and Surgical History 
Medical and surgical history  will be obtained at the Screening Visit. Medi cal history  will 
include a revi ew of the fo llowing systems: general, dermatological, respiratory , 
cardi ovascular, gastrointestinal , geni tourinary , gynecol ogical, endocrine, m uscul oskeletal , 
hematol ogical, neuropsychol ogical ,immune (allergies) ,and head, eyes, ears, nose, and throat. 
Historical and current medical condit ions including date of last menstrual period for female 
subject s will be recorded. 
16.3 Current Medical Conditions
At each visit after screening, subjects will be asked about any changes in medical condit ions, 
specifically new medical condit ions and worsening of exist ing medical condit ions. Any 
changes since the Screening Visit will be recorded as AEs, as appropriate. 
16.4 Physical Examination
A complete physical examinat ion will be performed at the Screening V isit and the Week 
24/Early T ermination Visit.The complete physical examinat ion includes evaluat ion of the 
head, eyes, ears, nose, throat, neck (including thy roid), cardi ovascular system  (including 
assessment of heart, peripheral pulses, presence or absence of edema), lungs, abdo men 
(including liver and spleen, bowel sounds), lymph nodes, musculoskeletal system (including 
spine, jo ints, muscles) neuro logical system (including cranial nerves , reflexes, sensat ion, 
strength), skin, extremit ies and other conditions of note.
A limited physical examinat ion, including evaluat ion of lungs, heart, abdomen, and
extremit ies will be done at all other visits . 
The findings of the physical examinat ions wi ll be recorded . Any change from  the Screening 
Vis
itphysical examinat ionthat is considered clinically  significant by  the investigator will be 
recorded as an AE. 

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 43of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt16.5 Height and W eight
Height will be collected at screening only . Weight will be co llected at spe cified times during 
the study .
16.6 Vital Signs
Vital signs will  be obtained after the subject has been seated for 5 minutes (minimum) and 
will include systo lic and diastolic blood pressures, pulse rate, respiratory rate, and body  
temperature .Additionally , atthe Screening and Baseline Visit s, blood pressure will be 
measured at least 3 times, with 5 minutes between assessments after the subject has been 
seated for a minimum of 5 minutes prior to the init ial blood pressure assessment.
The invest igator may perfo rm addi tional unscheduled vi tal sign measurements to evaluate or 
manage a suspected AE. These unscheduled vital sign measurements should be obtained after 
the subject has been seated for at least 5 minutes, if possible. Unscheduled vital signs will be 
recorded.
Thedate and time for allvital sign assessments will be recorded .
Screening/Baseline Assessments
A subject withsystolic blood pressure 140mmHg and diastolic blood pressure 90 mm Hg 
(average of 3 assessments) at the Screening or Baseline Visit s does not qualify for the study .
On Study Assessments
If an on -study  vital sign is not in the site’s standard reference range, a n AE will be recorded if 
the invest igator determines the change isclinically significant or requi res a change in the 
subject ’sclinical management. 
16.7 Clinical Laboratory T ests(Chemi stry, Hematology , Urinalysis , HbA1c , 
Hepatitis Serology , 
IGRA, and Pregnancy T ests)
The clinical laboratory  tests are listed in Section 32.1.All clinical laboratory  tests will  be done 
at a central laboratory  facilit yexcept u rine pregnancy  (at the si te),andIGRA  (local 
laboratory ). Specific instructions for collect ion, processing, storage ,and shipment of clinical 
laboratory  samples will be provi ded in a s eparate laboratory  manual , where appropri ate.
Samples for l aboratory  testing at all visits may  be collected under fasted or nonfasted 
condi tions. The date and time of the sample collectio n must be docum ented on the l aboratory  
report. Investigators must rev iew and sign lab oratory reports. The clinical significance o f each 

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 44of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtlaboratory  abnorm ality will be docum ented. New clinically significant laboratory 
abnorm alities or clinically  significant changes in laboratory  values will be reported as AEs, as 
appropriate .
Hem atologywith different ial, serum  chemistry , other specific tests, and urinalysis samples 
will be co llected at the specific t imes starting at screening and throughout the study .
In addit ion:
All female subjects of child -bearing potential will have a se rum pregnancy test at the
Screening and W eek24/Early T erminat ion Visit s. Urine pregnancy  testswill be done 
at all other visits throughout the study. Results must be available prior to dosing wit h 
protocol  mandated study  drug . Subj ects wi th posi tive resul ts will be ineligible for 
study  entry  (Screening Visitor Predose) or wi thdrawn fro m the study .Any female 
subject that becom es pregnant during the study  will be immediately  withdrawn and the 
pregnancy report as per Section 21.6.
If applicable, the subject’ s agreement to use contracepti onthroughout thei r study  
participat ion(through the Follow -up V isit)will be documented .
HBsAg and HBcAb will be performed at the Screening Visit. Resul ts of these tests 
must be negat ive or nonreactive for subjects to qualify for the study.
HCV antibody  testing will be performed at the Screening V isit.A positive HCV
antibody will autom atically trigger a HCV PCR analysis. HCV PCR m ust be < 25 
IU/m Lto qualify  for the study .
IGRA for TB will be performed at the S creening Visit.Results of this test must be 
negat ive for subjects to qualify for the study . 
HbA1c will be performedat the Screening Visit HbA1c must be ≤ 6.5% for subjects to 
qualify  for the study . Addit ional HbA1c tests will be done at specified t imes during the 
protocol .
Out-
of-Range Laboratory V alues
Laboratory  values fro m samples collected at the Screening Visit will be evaluated by  the 
investigator for eli gibili ty of the subject in the study . Clinical laboratory  tests m ay be repeated 
once to determine subject eligibilit y.

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 45of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtLaboratory  values that fall outside the reference range fro m samples co llected during the 
study  or at study  exit or early  terminat ion wil l be assessed by the invest igator for clinical 
significance. If the out of range value for samples is deemed clinically  significant by  the 
investigator, an AE will be recorded. 
17EFFICACY ASSESSMENTS
Efficacy assessments will be evaluated at tim es specifie d in the Schedule of Study  Events 
(Table 7 -1)forcomposite indices including DAS28 -ESR, ACR20 /50/70 , and CDAI ; as well 
asFACIT
-Fand HAQ -DI.
The DAS28 -ESR i s a validated composite index to assess disease activit y in RA(Prevoo et al, 
1995; DAS28 W ebsite, 2016 ) . The components of DAS28 -ESR include 28 Joint Count, 
General Healt h VAS, and ESR. 
The ACR has developed a core set of criteria for defining improvement in RAthat includes 28 
Joint Count, Patient Assessment of Pain, Patient Global Assessment of Disease Act ivity, 
Physician Glo bal Assessment of Disease Act ivity, Patient’s Assessment of Physical Function
using the HAQ -DI,and an acute phase reactant (ESR or CR P). T ypical thresho lds for ACR 
improvement are 20%, 50% and 70% (ACR20, ACR50, ACR70) , with the percentages 
referring to the i mprovement in tender and sw ollen jo ints plus improvement in 3 of the 5 other 
components (Felson et al, 1995 ;Felson and LaV alley, 2014 ;Pincus, 2005 ).
The CDAI i s a validated composite index that was developed to simplify  disease activit y
assessment in RA(Aletaha and Smo len, 2005) and consists of 28 J oint Count, Patient Global 
Assessment of Disease Act ivity, and Physician Global Assessment of Disease Act ivity
.
The F ACIT -F is validated to questionnaire used to assess fatigue in RA  (Cella et al , 2005 ) .
The HAQ -DI is a validated 20 item quest ionnaire to assess funct ional activity in specific tasks 
(Bruc e and Fries, 2003 ). 
Below aregeneral instruction s forthe administration of these assessment s. Specific
instructi ons and quest ionnaires will be provided a se parate document.
17.1 28 Joint Count
The 28 Joint C ount includes assessment of swelling and tenderness in the shoulders, elbows, 
wrists, metacarpophalangeal jo ints, proximal interphalangeal jo ints and knees. The 28 Joint 
Count will be co mpleted by  the invest igator or designee. The same rater should assess the 
subject at every  visit.

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 46of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt17.2 Subject C ompl eted Efficacy Questionnaires
The General Healt h VAS, Patient Assessment of Pain, Patient Global Assessment of Disease 
Activity,Patient Assessment of Physical Funct ionby HAQ -DI,andFACIT-F are 
questionnaires to be com pleted by subjects. When these assessments are required, they  shoul d 
be the first assessment sdone at any  visit and must be com pleted pri or to any study  drug 
dosing. Subjects will be provided a quiet, private place to complete the assessments. Subjects 
will be instructed to answer all quest ions to the best of their abilit y and without help fro m 
others (including study  staff, relatives, or friends). The study  staff should review the 
questionnaires after they  are com pleted and encourage the subjects to complete any  missing 
inform ation. Subjects may refrain fro m answering any quest ion. Study  staff will record the 
refusal of subjects to answer any quest ions in the source documents. 
17.3 Physician Completed Efficacy Questionnaires
The Physician Glo bal Assessment of Disease Act ivity is a quest ionnaire to be com pleted by  
the invest igator or designee . When thi sassessment isrequi red, itshould be the first 
asses sment done at any  visit and must be com pleted pri or to any  study  drug dosing.
17.4 ESR and CRP
Blood sam ples f or eval uation of  ESR and CRP will be collected at tim es specified in the 
Schedule of Study  Events ( Table 7 - 1). Samples for ESR will be analyzed at the site. CRP 
samples will be shipped to a central laboratory
.
Specific instructions for collect ion, processing, storage, and shipment of samples for ESR and 
CRP will be provi ded in a separate laboratory  manual .
 
 
 
 
 
 

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 47of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt 
 
 
 
 
 
 
 
 
 
 
 
20STATISTICAL  METHODS AND PLANNED ANAL YSIS
20.1 General Considerations
This sect ion provi des a general descript ion of the statist ical methods to be used in analyzing 
both safet y and efficacy data. The key statist ical issues or considerat ions will be addressed. 
 
Unless otherwise specified, all statist ical tests will be 2-sided wi th a signif icance level o f 0.05. 
Summary  statistics will be provided for all study  variables wit h descriptive statist ics (number 
of observati ons, m ean, standard deviat ion, median, minimum, and maximum) for numerical 
(or continuous) variables. Frequency and percentage s will be calculated for categorical 
variables. All data will be summarized for Part 1 with 1 treatm ent group and for Part 2 with 2 
treatm ent groups as appropriate. Data summary and analyses will be performed with SAS 9. 2
or higher.

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 48of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt20.2 Analysis Populations
TheModified Intentto Treat (mIT T)Populationwillinclude all enrolledsubjectswho
receive 1 ormoredosesofstudy  drug andwho contrib u teanyefficacy data tothe study.
ThePer
-Proto colPopulation will in clude t hesubse t of the mITTpopulation w ho
c
ompletethe study asperprot ocol.
TheSafetyPopu lation will include all en rolledsubjectswho r eceive 1 ormoredosesof
study  drug .
20.3 Endpoints
20.3.1 Primary Efficacy Endpoint
The primary  efficacy endpo int will be the proportion of subjects with DAS28 -ESR < 3.2 at 
Week 12.
20.3.2 Secondary Efficacy Endpoints
Proporti on of  subjects who m aintained DAS28 -ESR < 3.2 from W eek 12 through 
Week24.
Time to disease act ivity flare fro m Week 12 through W eek 24.
Proporti on of  subjects wi th CDAI ≤ 10 at W eek 12.
Proporti on of  subjects who m eet cri teria for ACR20 at W eek 12.
20.3.3 Secondary Safety Endpoints
Summary  of general safet y profile, including adverse events (serious and non- serious), 
vital signs and l aboratory  assessments by study  period and over the ent ire study .
20.3.4 Exploratory Endpoints
Exploratory Efficacy Endpoints

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 49of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt  
Exploratory Health Outcomes Related Endpoints

 
 
Exploratory 
 
20.3.5 Subje ctCharacteristics
20.3.5.1 Demographics
The demographic informat ion will be summarized for each analysis populat ion by treatment 
group .
20.3.5.2 Medical and Surgical History
Relevant prior medical condit ions or procedures will be summarized by  body system  and 
treatm ent group.
20.3.5.3 Prior and Concomitant Medications
Prior and concomitant medicat ions will becoded according to the WHO Drug Dict ionary. The 
incidence (number and percent) of prior and concomitant medication use will be summarized 
by treatment group.

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 50of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt20.3.5.4 Subject Disposition and Exposure to Study Drug
Subject disposit ion will be summarized for all en rolled subjects in Part 1 and all rando mized 
subject sin Part 2. The number of subject s who complete the study  and who do not com plete 
the study along wi th the reasons for discontinuati on from the study will be summarized.
20.3.6 Safety Analysis 
All subject s who receive at l east 1 dose of study  drug will be included in the safety analyses. 
Safety data will be summarized descript ively or graphically , as appropri ate.
20.3.6.1 Adverse Events
Adverse events will be coded using the appropri ate versi on of MedDRA . All AEs will be 
presented in a data list ing. Only treatment -emergent adverse events (TEAEs) (events that are 
new in onset or aggravated in severit y following treatment) will be included in all summaries.
TEAEs will be summarized foreach treatment gr oup, by  system  orga n class and preferred 
term. Seri ous adverse events (including death) will be summarized. In addition, adverse 
events will be summarized by severit y and relat ion to study  drug.
20.3.6.2 Clinical Laboratory T ests
Hem atology, blood chemistry , urinalysis and HbA1c results will be summarized at baseline 
and at each visit by treatment group. Change fro m baseline to each visit will also be 
summarized. Abnormal lab oratory values will be ident ified and analyzed.
20.3.6.3 Vital Signs
Vital sign resul ts (heart rate, di astolic/systoli c blood pressures, respi ratory  rate, and body  
temperature) and corresponding changes from baseline values will be summarized at each 
visit withdescriptive statistics by treatm ent group.
20.3.6.4 Other Safety Analysis
Other safet y assessments including physical ex aminat ions, weight, and pregnancy testing, will 
be analyzed with appropri ate summary  statistics .
20.3.7 Efficacy Analysis
All efficacy analyses will be performed on the mITT.Selected analyses will be performed on 
the Per-protocol  Population.

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 51of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtFor the primary  endpo int, the proportion of subjects with LDA  at W eek 12 al ong wi th a 2-
sided 95% confidence interval will be provided. The lower bound of the 95% confidence 
interval  will be used to evaluate the response rate. The study  will be deem ed successful  if the 
lower bound of the 95% confidence interval is greater than or equal to 10%.
For the secondary  endpoints, t he proporti onsof subjects who m aintain LDA  in Part 2 for the 2 
treatm ent groups will be co mpared using a 2- sided Pearson’ s chi -square test at a signifi cance 
level of 0.05. The t ime to disease activit y flare in Part 2 will be analyzed using log -rank test.
The p roporti on of  subjects with CDAI ≤ 10 at W eek 12 and the proporti on of  subjects who 
meet criteria for ACR 20 at W eek 12 will be analyzed using the same method as that for the 
primary  endpoint.
For the exploratory  endpoints, 
 
 
 
 
 
 
 
 
 
 
 

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 52of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt20.6 Interim  Analysis
The study  resul ts from Part 1 will be summarized when all subjects complete the Part 1 of the 
study . No other interim analyses are planned for this study .
20.7 Statistical Power and Sa mple Size Considerations
It is expected that 360 subjects will be sc reened and a total of 232 subjects will be enrolled in 
this study . It is estimated that 55% of subjects willeither drop out before Week 12 or will no t
achieve LDA  by Week 12. The remaining 45% of subjects will have achieved LDA  after 12 
weeks of treatment with Acthar and will be randomized into 2 treatment groups in Part 2 of 
the study . Based on results from previous studies ( Pincus,2011 )and (Ruperto et al, 2008) , it is 
estimated that 80% ofthe Acthar group and 50% of the placebo group will maintain LDA  
after the 12 addit ional weeks o f treatm ent.Assuming that 52 subjects per group (104 subjects 
total) will  com plete Part 2, and based on the use of a 2
-sided, 2-sample comparison of 
proporti onsat the alpha = 0.05 level o f significance, there will be 90% of  power to detect a 
difference in the 2 treatment groups.
20.8 Deviations From Statistical Analysis Plan
Any deviat ions from the planned stati stical analysis will be described and just ified in the final 
clinical study  report as appropriate.
21ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS
21.1 Safety
For safet y informat ion about Acthar refer to the most recent versio n of the Prescribing 
Inform ation(Mallinckrodt ARD , 2015 )
 and the Investigator ’s Brochure ( Mallinckrodt, 2016 ). 
21.2 Definitions
Adverse Event 
An AE is any untoward or undesirable medical occurrence in a subject who is administered 
IMP, which does not necessarily  have to have a causal relat ionship with this treatment.
Examp les of AEs include but are not limited to:
Clinically significant laboratory  findings .
Clinically significant changes in physical examinatio n findings .
An AE occurring due to IMP overdose whether accidental or intent ional.

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 53of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtAn AE occurring from IMP abuse .
An AE associated with IMP withdrawal .
Unexpected Adverse Event.
An unexpected AE is defined as an AE, the nature and severit y of which is not consistent with 
the applicable product informat ion in the most recent versio n of the Invest igator ’s Brochure.
Serious Adverse Event 
An SAE is defined as any untoward medical occurrence that at any  dose resul ts in any of the 
following outcom es:
Death .
A life-threatening AE .
Inpatienthospi talizat ion or prolongat ion of exist ing hospi talizat ion.
A persistent or sign ificant incapacit y or substantial disruption of the abilit y to conduct 
norm al life f unctions.
Results in a congenital ano maly/birth defect .
Important m edical events that may not result in death, be life -threatening, or require 
hospi talizati on may  be consid ered seri ous when, based upon appropriate medical judgment, 
may jeopardize the subject or subject and may require medical or surgical intervent ion to 
prevent one of the outcomes listed above. Examples of such medical events include allergic 
bronchospasm re quiring intensive treatment in an emergency depart mentor at hom e, blood 
dyscrasias or convulsions that do not result in inpatient hospitalizat ion, or the development of 
drug dependency  or drug abuse.
Death 
Death i s an outcome of an event. The event that resulted in death should be recorded and 
reported on the SAE Form. All causes o f death m ust be reported as SAEs. The invest igator 
shoul d make every  effort to obtain and send death certificates and autopsy  reports to 
Mallinckrodt.
Life-Threatening Event 
A life-threatening event refers to immediate risk o f death as the event occurred per the 
reporter . A life-threatening event does not include an event that, had it occurred in a more 

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 54of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtsevere form, might have caused death but, as it actually occurred, did not c reate an immediate 
risk of death. For example, hepatit is that resolved without evidence of hepat ic failure would 
not be considered life -threatening, even though hepatit is of a more severe nature can be fatal. 
Similarly , an allergic react ion result ing in an gioedema of the face would not be life -
threatening, even though angioedema of the larynx, allergic bronchospasm, or anaphylaxis can 
be fatal.
Hospitalization 
Hospitalization is defined as an official admission to a hospital. Hospitalizat ion or 
prolongati on of a hospi talizat ion const itutes a criterion for an AE to be serious; however, it is 
not in itself considered an SAE. In absence of an AE, a hospi talizat ion or prolongat ion of a 
hospi talizati on shoul d not be reported by  the investigator as an SAE. S uch s ituations include, 
but are not limited to, the following:
A hospi talizat ion or prolongation of hospitalization is needed for a procedure required by the 
protocol .
A hospi talizat ion or prolongation of hospitalization is part of a routine procedure followed by 
the center (eg, stent removal after surgery). This should be recorded in the study file.
A hospi talizat ion for a preexisting condit ion that has not worsened.
Note that t he fo llowing hospi talizat ions are not considered SAEs in Mallinckrodt clinical 
studi es: 
A visit to the emergency departm entor other hospital department of less than 24hours that 
does not result in admissio n (unless considered "important medical event" or life -threatening 
event).
21.3 Adverse Event and Serious Adverse Event Classifications
Study Drug Relatedness
The following cl assificat ions should be used when evaluat ing the relat ionship of AEs or SAEs 
to study  treatm ent (Table 21 - 1).

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 55of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtTable 21–1: Adverse Event Relat ionships
Relationship Definitio n
Not Related No relationship between the experience and the administration of study treatment; 
related to other etiologies such as concomitant medications or subject ’s clinical state.
Unlikely  Related The current state of knowledge indicates that a relationship is unlikely.
Possibly Related A reaction that follows a plausible temporal sequence from administration of the study 
treatment and follows a known response pattern to the suspected study treatment. The 
reaction might have been produced by the subject ’s clinical state or other modes of 
therapy  administered to the subject .
Related A reaction that follows a plausible temporal sequence from administration of the study 
treatment and follows a known response pattern to the suspected study treatment and can 
be confirmed with a positive re -challenge test or supporting laboratory data.
Severity Assessment
For purposes of consistency , if required the invest igator may use the intensit y grades 
presented in Table 21 -2.
Table 21–2: Adverse Event Severity Grades
Grade Definitio n
Mild Does not interfere with subject 's usual function and activities
Moderate Interferes to some extent with subject 's usual functio n and activities
Severe Interferes significantly with subject 's usual function and activities
If an AE increases in severit y (eg, fro m mo derate to severe); decreases in severit y (eg, 
changes fro m mo derate to mild); or there is a change in seriousness, a new AE will be opened 
and the original AE will be closed. If an AE is still ongoing at the time o f a subject ’s 
completion of the fo llow-up visit, the resol ution/stop date and time is left blank. 
To ensure there is no confusion or misunderstanding of the difference between the terms 
“serious” and “severe,” which are no t synonymous, the fo llowing note of clarificat ion is 
provi ded:
The term  “severe” is used to describe the intensit y (severit y) of a specific event (as in mild, 
moderate, or severe my ocardi al infarct ion); the event itself, however, may be of relat ively 
minor medical importance (such as a severe headache). This is not the same as “serious,” 
which is based on the subject /event outcome or actio n criteria usually  associated wi th events 
that pose a threat to a subject 's life or funct ioning. Seri ousness (not severi ty) serves as a guide 
for defining regulatory  reporting obligations.

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 56of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt21.4 Adverse Event and Serious Adverse Event Recording and Reporting
AEs and SAEs will be recorded from signing of the ICF through complet ion of the fo llow-up 
visit. The invest igator is required to record the AE or SAE regardless of the severit y of the 
event or its relationship to study  treatm ent. Prior to the Baseline V isit/Visit 2 , only  AEs and 
SAEs related to study  procedures will be recorded. The invest igator mus t follow up on all AEs 
and SAEs reported to have occurred 30 days after study  com pletion until the even thas
resolved or stabilized or at such time the invest igator refers the subject to anonstudy 
physician. The invest igator will document the further fo llow-up informat ion in the subject ’s 
source document.
During the period specified above, the invest igator will:
Record all AEs and SAEs from the signing of the ICF through the complet ion ofthe 
End of Study /Early Terminat ionvisit.
Report all SAEs on an SAE Report Formto Global Pharmacovigilance .
Report all pregnancies to Global Pharmacovigilance on the Pregnancy  Surveillance 
Form .
Submit any Expedited Safet y Report or Suspected Unexpected Serious Adverse 
React ionfrom Global Pharmacovigilance to the IRB /IEC .
The reporti ng requirements for AEs are summarized in Table 21 -3.
Table 21–3: Reporting Requir ements for  Adverse Events
Seriousness Reporting Time Type of Report
All SeriousWithin 24 hours of first knowledge of 
eventInitial report on the SAE Form, appropriate 
eCRF, and source document
Within 24 hours of receipt of follow -up 
informationFollow up report on the SAE Form, appropriate
eCRF, and source document
NonseriousPer case report form submission 
procedureAppropriate eCRF and source document
Adverse Events
Adverse events can be reported spontaneously or elicited during open -ended quest ioning ( ie, 
"How have you been feeling since y our l ast vi sit?"), examinat ion, or eval uation of a subject .
Signs and symptom s must be recorded using standard medical termino logy. For subject s 

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 57of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtincapable o f giving consent, the legally  acceptable representative may  provide informat ion 
regarding the subject ’s status.
All fields on the AE CRF page should be co mpleted for each event with a full descript ion of 
the event and date of onset/start and resolut ion/stop. A medical diagnosis if known, should be 
recorded in lieu of each individual sign and sympt om associated with the diagnosis and 
experienced by the subject . If no medical diagnosis is known, the term used by the subject to 
describe the event or signs noted by  the si te personnel shoul d be recorded. 
Serious Adverse Events
Initial Reporting
Seriousadverse event s (based on FDA/ICH definit ion of an SAE) require immediate reporting 
to Global Pharmacovigilance . 
For all SAEs, the invest igator , or desi gnee, m ust com plete the SAE Report Form with 
the minimum informat ion required by FDA  and ICH and fax i t to Mallinckrodt at 
+1314-654- 5759 or em ail at GlobalPV@mallinckrodt.com within 24 hours of first 
knowl edge of the event even if the experience does not appear to be related to the 
IMP.
The invest igator ,or desi gnee ,will receive acknowledgement of recei pt of the SAE 
Report F orm from Mallinckrodt.
Shoul d the invest igator or designee have any difficult y in sending the SAE Report, 
they may contact Mallinckrodt based on the informat ion in the Study  Operati ons 
Manual.
If there is any doubt about whether the informat ion consti tutes an SAE, the 
inform ation is to be treated as an SAE.
The invest igator(s) or designee is required to submit the any Expedited Safety  Report or 
Suspected Unexpected Serious Adverse React ion to the responsible IRB/ IEC.
The sponsor will ensure that any Expedited Safet y Report or Suspected Unexpected Serious 
Adverse React ionare submitted to the FDA and other regulatory  agencies as appropriate .

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 58of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtFollow  Up Reporting 
The invest igator or designee must complete an SAE Report Form for all fo llow-up 
inform ation received and fax it to Mallinckrodt at +1 314-654- 5759 within 24 hours of 
recei pt. The invest igator(s) or designee will receive acknowledgement of receipt for each SAE 
Report F orm from Mallinckrodt.
The invest
igator or designee is requir ed to provi de all  related inform ation/supporting 
docum entati on ofan SAE until the SAE is reso lved or stabilized or the subject has 
been referred to a nonstudy  physician for follow-up treatment .
The invest igator(s) or designee is required to submit the Safet y Alert to the responsible 
IRB/ IEC. 
The sponsor will ensure that any Expedited Safet y Report or Suspected Unexpected 
Serious Adverse Reaction are submitted to the FDA and other regulatory  agencies as 
appropriate .
21.5 Adverse Events of Special Interest
AEs of special interest for this study  are outlined below. Adverse events of special interest 
will be fo llowed unt il resolut ion or return to baseline.
Elevated blood pressure (defined as systolic blood pressure ≥ 180 anddiastolic blood 
pressure ≥ 100 mm Hg).
Hyperglycemia (HbA1c > 6.5%, or fasting plasma glucose > 126 mg/dL, or classic 
symptoms of hyperglycemia wit h rando m plasma gl ucose > 200 m g/dL) .
MedDRA  System  Organ Class infect ion/infestation of ≥ moderate intensit y.
AEs considered possibly , probably , or definitely related to IMP treatment of ≥ moderate 
intensity.
Hy’s Law cases (AL T > 3 x ULN, with total bilirubin > 2 x ULN , noinitial signs of 
cholestasis [al kaline phosphatase within the reference range]) , and no other reason can 
be found to expl ain liver injury ).
21.6 Pregnancy Reporting
Certain informat ion, although not considered an SAE, must be recorded, reported, and 
followed up as indicated. This incl udes the foll owing: 

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 59of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtPregnancy exposure to an invest igational medicinal product, except f or exposure to prenatal 
vitamins. Subject s should not become pregnant during the study . If the subject beco mes 
pregnant, study  treatm ent m ust be discont inued immediately . The investigator must report the 
pregnancy by  submitt ing the appropri ate form  to Global Pharmacovigilance (fax at 
+1 314-654- 5759 or em ail at  globalpv@mallinckrodt.com ) within 24 hours of confirmat ion of 
apregnancy (ie, posit ive serum pregnancy test result) . The outcome of pregnancy (eg, 
spontaneous abortion, live birth, still birth, congenital ano malies, birth defects) must be 
reported by submitting the appropriate form to Global Pharm acovigilance (fax at + 1 314-654-
5759 or em ail at
 globalpv@ mallinckrodt.com ) within 24 hours of the pregnancy outcome 
being submitted to the study  site. If the pregnancy results in a live birth, a post delivery fo llow-
up will be performed at least 28 days after the baby is born andmust be reported to Global 
Pharmacovigilance (fax at + 1 314-654- 5759 or ema il at globalpv@mallinckrodt.com ) within 
24hours of the study  site becoming aware of the follow -up informat ion. Both m aternal  and 
paternal  invest igational medi cinal product exposures are collected. 
If the female partner of a male subject beco mes pregnant during the study , the si te will  
forward the Pregnancy Notification form and the Pregnancy Report Fax cover page to Global
Pharmacovigilance (fax at + 1 314-654- 5759 or ema il at globalpv@mallinckrodt.com ), within 
24 hours of being notified. The outcom e of pregnancy (eg, spontaneous abortion, live birth, 
still birth, congenital ano malies, birth defects) must be repor ted by  submi tting the appropriate 
form to Global Pharm acovi gilance (fax at + 1 314-654- 5759 or ema il at 
globalpv@mallinckrodt.com ) within 24 hours of the pregnancy  outcome being submitted to 
the study  site. If the pregnancy results in a live birth, a postdelivery  follow-up will be 
perform ed at l east 28 days after the baby  is born and must be reported to Mallinckrodt 
Pharmacovigilance (fax at + 1 314-654- 5759 or ema il at globalpv@mallinckrodt.com ) within 
24hours of the study  site becoming aware of the follow -up informat ion.
22SUBJECT DISCONTINUA TION OR WITHDRA WAL
22.1 Subject Withdrawal
Subject s who discont inue, or are withdrawn fro m the study  for any  reason, will be required to 
enter the fo llow-up period and have the Early T erminat ionand Fo llow-up safet y assessments 
(see Secti on 14.5 andSecti on 14.6 ) to assess their continued well-being. 
The reason for discontinuat ion will  be recorded . A subject may be discont inued fro m the study  
for the fo llowing m edical  or administrat ive reasons:

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 60of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtWithdrawa l by Subject
Subject s will be free to discont inue from the study  at any  time. Subject s who have received at 
least 1dose of study  drug but do not complete the study will not be replaced.
Adverse E vent
If a dosed subject suffers an AE that, in the judgment of the investigator , sponsor or MM, 
presents an unacceptable consequence or risk to the subject , the subject will be discont inued 
from further participat ion in the study .In addit ion, adverse events outlined in Section 15.3.1
will require subject withdrawal.
Death
In the event that a subject dies during the study , death will be the reason for discont inuat ion.
Lost to Follow -up
Every  effort shoul d be used to m aintain contact w ith subjects during their participat ion in the 
study . A subject m ay be considered lost to follow
-up if  there is no response to 3 attempts to 
reach the subject by  telephone and no response to a certified letter sent to the last known 
address of the subject .Efforts to contact the subject should be noted in source documentation.
Met Withdrawal Criteria
If a subject develops a condi tion that m eets any o f the exclusio n criteria (Secti on 12.2)or fails 
to meet an inclusio n criteria (Secti on 12.1) during the study  that i s not considered to be an AE 
or is nonco mpliant (eg, has a posit ive pregnancy or drug screening test), the subject will be 
discontinued fro m further participat ion in the study .Discontinuation is also mandated for 
safet y and/or tol erabili ty issues as outlined i n Section 15.3.1.
Worsening of Disease Activity
Subjects will be wit hdrawn if they have a flare/worsening of disease act ivity defined as:
Weeks 0 to 11:DAS28 -ESR ≥ 3.2 and increase of 0.6 fro m the Week 0 assessment 
sustained over 2 consecutive study  visits; or DAS28
-ESR ≥ 3.2 and increased of 1 
from the Week 0 assessment at a single visit.

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 61of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtWeeks 13 to 23:DAS28 -ESR < 3.2 and increase of 1.2 from the W eek 12 assessment; 
or
 DAS28 -ESR ≥ 3.2 and increased of 0.6 from the W eek 12 assessment sustained 
over 2 consecut ive study  visit s;or DAS28 -ESR ≥ 3.2 and increase o f 1 fro m the 
Week 12 assessment at a single visit .
Other
If the above reasons are not applicable, please use th e “Other” option and provide the 
appropriate reason for subject withdrawal.
23STUDY SUSPENSION, TERMINA TION, AND COMPLETION
The sponsor may suspend or terminate the study  or part of the study  at any  time for any  
reason. If the invest igator suspends or termin ates the study , the invest igator will pro mptly 
inform  the sponsor and the IRB /IEC and provide them with a detailed written explanat ion. 
Upon study  com pletion, the invest igator will provide the sponsor, IRB /IEC , and regulatory  
agency  with final reports and summaries as required by regulat ions. Study  terminat ion and 
follow-up will be performed in co mpliance with Mallinckrodt standard operating procedures. 
24PROTOCOL  AMENDMENTS
Any change in the study  plan requi resa protocol  amendment. Aninvest igator must not make 
any changes to the study  without IRB /IEC and sponsor approval except when necessary to 
eliminate apparent immediate hazards to the subject s. A protocol change intended to eliminate 
an apparent immediate hazard to subject s may be implemented immediately , but the change 
must then be documented in an amendment, reported to the IRB /IEC within 5 working days, 
and submitted to the appropriate regulatory  agency in the required time frame. 
25QUALITY CONTROL  AND ASSURANCE
The sponsor performs qualit y control and assurance checks on all clinical studies that it 
sponsors. Before enrolling any  subject s in this study , sponsor personnel and the invest igator
review the protocol, the I nvestigator ’s Brochure , the eCRFs and instructions for their 
completion, the procedure for obtaining informed consent, and the procedure for reporting 
AEs and SAEs. A  qualified representative of the sponsor will mo nitor the conduct of the 
study . During these study  site visi ts, inform ation reco rded i n the eCRFs will be verified 
against source documents.
25.1 Study and Study Site Discontinuation Criteria
The sponsor , invest igator , or local and nat ional regul atory  authori tiesmay discover condit ions 
during the study that indicate that the study  or study site shoul d be terminated. This action 

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 62of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtmay be taken after appropriate consultat ion between the sponsor and invest igator . Condit ions 
that may  warrant terminat ion of the study /study  site include, but are not limited to:
The discovery  of an unexpected, seri ous, or unacceptable risk to the subject s enrolled 
in the study .
The decisio n on the part of the sponsor to suspend or discontinue testing, evaluat ion or 
development of the IMP.
Failure of the invest igator to enroll subject s into the study  at an acceptable rate.
Failure of the invest igator to com ply with pertinent regulat ions.
Submissio n of knowingly  false inform ation from the study  site to the sponsor , study 
monitor, or local and nat ional regulatory  authori ties.
Insufficient adherence to protocol requireme nts.
Study /study  site terminat ion and fo llow-up will be performed in co mpliance wit h 
Mallinckrodt standard operating procedures .
26DIRECT ACCESS, DA TA HANDLING, AND RECORD -KEEPING
26.1 Investigator
The invest igator will permit study -related m onitoring, audi ts, IRB/IEC review , and regul atory  
inspections by providing direct access to original source data and documents.
All subject informat ion will b e recorded on source documents. The eCRFs must be fully 
completed and include all required data for all subject s enrol led. All eCRF data must be 
submitted to the sponsor throughout and at the end of the study .
If aninvest igator retires, relocates, or otherwise withdraws fro m conduct ing the study , the 
investigator must notify the sponsor to agree upon an acceptable stora ge solut ion. Regulatory  
agencies will be notified with the appropriate documentation.
Any significant changes in study  personnel will requi re an updated Statement of Invest igator 
(ie, FDA  form 1572) to be filed with the sponsor .
The invest igator must notify their IRB /IEC of protocol deviat ions in accordance with local 
regul atory  and IRB /IEC requi rements.

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 63of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt26.2 Sponsor
The eCRF data are stored in a database and processed electronically . The sponsor ’s MM 
reviews the data for safety  informat ion. The data are reviewed for completeness, and logical 
consistency . Automated validat ion program s will ident ify missing data, out -of-range data, and 
other data inconsistencies. Clinical laboratory  data will be processed electronically . Requests 
for data cl arificat ion are forwarded to the study site for resol ution.
27SUBJECT INJUR Y
In general, subject to specific provisio ns in the clinica l trial agreement, if a subject is injured 
as a di rect resul t of an invest igational medicinal product, the sponsor will pay for reasonable 
and necessary medical treatment for the injury , to the extent that such expenses are not 
covered by  the subject ’s medical insurance, a government program, or other responsible third 
party . If laws or regul ations of the l ocali ty in which the study  is taking pl ace requi re addi tional 
payment of expenses, the sponsor shall co mply with such laws or regul ations. Where 
applicable, the sponsor has taken specific nat ional insurance.
28RECORDS RETENTION
The invest igator shall retain and preserve 1 copy of all data collected or databases generated 
in the course of the study , specifically including but not limited to those defined by  GCP as 
essent ial. Essent ial docum ents shoul d be retained unt il at least 2 years after the last approval 
of a market ing applicat ion in an ICH region and until there are no pending or contemplated 
market ing applications in an ICH region or at least 2 years ha ve elapsed since the formal 
discontinuat ion of clinical development of the investigat ional medicinal product. These 
docum ents shoul d be retained for a l onger period, however, if required by the applicable 
regul atory  requi rements or by  an agreement with the sponsor . It is the responsibilit y of the 
sponsor to inform the invest igator /institution as to when these documents no longer need to be 
retained. Prior to destruction of any study  essent ial docum ents, the invest igator must first 
obtain written approval fr om the sponsor . 
29BIOLOGICAL  SAMPLES
Blood sam ples will be used only for scient ific research. Each sample will be labeled with a 
code so that the laboratory  personnel testing the samples will not know the subject ’s identity.
After the study  ends, the clinic al laboratory  samples will be destroy ed, with the except ion of 
 
will be retained at a bio logic storage facility  for future testing. The subject may 
request that h is or her samples, if st ill ident ifiable, be destroy ed at any  time; however, any 
data al ready  collected from  that sam ple will st ill be used for this research. 

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 64of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt30PUBLICA TION POLICY
30.1 Sponsor’ s Publication Policy
The sponsor ’s policy is to publish or otherwise communicate the results of its hypothesis -
testing clinical studies, regardless of outcome, for marketed products, compound(s) or 
product(s) being invest igated that are later approved for market ing. Hypothesis -testing clinical 
studi es are those studi es inte nded to provide meaningful result s by examining prestated 
questions using predefined statist ically valid plans for data analysis, thereby providing firm 
evidence of safet y and/or efficacy to support product claims.
Exploratory  studi es, in contrast, serve t o set direct ion for possible future studies. They have 
significant stati stical limitat ions, provide only  preliminary  information about a disease, 
condi tion, or product, and are not designed to provide final conclusions on product claims. 
The sponsor does n ot commit to publish or otherwise communicate the results of every  
exploratory  study , because this information is of an exploratory  nature and often highly 
propri etary . However, if informat ion from an explo ratory  study  is of significant medical 
importance, the sponsor will publish or otherwise communicate the results.
The sponsor ’s decisi on to publish or otherwise publicly  communicate the resul ts of this study  
will be made in accordance with all applicable laws, regulat ions, and sponsor policies 
regarding p ublicat ion and communicat ion of clinical study  resul ts.
30.2 Investigator’ s Ability to Publish
Terms and provi sions of  publicati on rights are governed by  the Publicati on Sect ion in the 
clinical trial agreement.

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 65of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt31REFERENCES
Ahmed, T .J.; Montero- Melendez, T .; Perretti, M.; Pitzalis, C. Curbing Inflammat ion Through 
Endogenous Pathway s: Focus on Melanocortin P eptides. Int. J. Inflam . 2013 , 143, 464-469.
Aletaha, D.; Neogi, T .; Silman A.J.; Funovits, J.; Felson, D.T .; Bingham, C.O.; et al. 2010 
American Co llege of R heumatoi d Arthrit is Classification Criteria: an American College of 
Rheumatology /European League Against Rhe umatism Co llaborative I nitiative. Arthritis 
Rheum . 2010 , 62, 2569-2581.
Aletaha, T .; Sm olen, J. The Simplified Disease Activit y Index (SDAI) and the Clinical 
Disease Activit y Index (CDAI): A Review of Their Usefulness and V alidity in Rheumatoi d 
Arthri tis. Clin. Exp.Rheumatol . 2005 , 23, S100 -S108.
American Psychiatric Associat ion. Diagnostic and Statistical Manual of Mental Disor ders (5th
Edition). 2013. W ashington, DC.
Arend, W .P. Physi ology of Cytokine Pathways in Rheumatoid Arthrit is. Arthritis Rheum . 
2001, 45, 101 - 106.
Arend, W .P. The Mode of Action of C ytokine I nhibitors. J.Rheumatol . 2002 , 65, 16-21.
Bijlsma, J.W . J.; Boers, M.; Saag, K.G.; Furs t, D E. Glucocortico ids in the Treatment of Early 
and L ate RA. Ann.Rheum . Dis . 2003, 62, 1033 -1037.
Brown, A.N. Adrenocorticotropic Hormone Gel in Patients with R efractory  Rheumatoi d 
Arthri tis:A Case S eries. Int. J.Clin. Rheumatol. 2015 , 10, 391-398. 
Bruce, B.; Fries, J.F . The Stanford Health Assessment Questionnaire: Dimensio ns and 
Practi cal Applicat ions. Health Qual .Life Outcomes . 2003, 1, 20.
Buch, M.H.; Boyle, D.L.; Rosengren, S.; Saleem, B.; Reece, R.J. ; Rhodes, L.A.; et al. Mode 
of Action of  Abatacept in Rheumatoid Arthrit is Patients H aving Failed Tumor Necrosis Factor 
Blockade: A Histologi cal, Gene Expressio n and Dynamic Magnet ic Resonance Imaging Pilot 
Study. Ann .Rheum . Dis . 2009, 68, 1220 -1227.
Buggy , J.J. Binding of Alpha -melanocy te Stimu lating Hormone to its G -protein Coupled 
Receptor on B -lymphocy tes A ctivates the Jak/ST AT Pathway . Biochem . J. 1998, 331, 211 -
216.

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 66of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtCapell, H.A.; Madhok, R.; Hunter , J.A.; Porter , D.; Morrison, E.; Larkin, J.; et al. Lack of 
Radiological and Clinical  Benefi tOver T wo Y ears of Low Dose Predniso lone for Rheum atoid 
Arthri tis: Results of a Rando mized Controlled T rial. Ann .Rheum . Dis . 2004 , 63, 797-803.
Cella, D.; Y ount, S.; Sorensen, M.; Chartash, E.; Sengupta, N.; Grober, J. V alidat ion of the 
Funct ional Assessm ent of Chronic Illness Therapy Fat igue Scale Relat ive to Other 
Instrum entati on in Rheumatoi d Arthritis. J.Rheumatol. 2005 , 32, 81 1-819.
Chikanza, I.C.; Kozaci, D.L. Corticosteroid Resist ance in Rheumatoid Arthrit is: Mo lecular 
and Cellular Perspectives. Rheumatol . 2004 , 43, 1337-1345.
Clark, W .S.; T onning, H.O.; Kulka, J.P .;Bauer, W . Observati ons on the Use of Corti sone and 
ACTH in Rheumatoid A rthritis. N. 
Engl . J.Med. 1953 , 249, 635-642.
Cooray , S.N.; Clark, A. J. L. Mela nocortin Receptors and Their Acce ssory  Proteins. Mol. Cell. 
Endocrinol . 2011, 331, 215-221.
DAS28 W ebsite 2016. www .das-score.nl /das28/en/introduction- menu.html (accessed 24 
February  2014) .
Decker, D.; Higgins, P .; Bend ele, A.; Becker, P . Repository  Corticotropin Inject ion (H.P . 
Acthar®Gel) A ttenuates Established Co llagen -induced Arthri tis When Used Alone or as an 
Adjuvant Therapy W ith Etanercept (Enbrel®) (THER5P .902). J
.of Immunol . 2015 , 194 (Suppl 
1), 139.4.
Feldmann, M.; Maini, R.N. TNF Defined as a Therapeutic T arget for Rheumatoid Arthri tis 
and Other Autoimmune D iseases. Nature Med . 2003 , 9, 1245-1250.
Felson, D.T .; Anderson, J.J.; Boers, M.; Bombardier, C.; Furst, D.; Goldsmit h, C.; et al. 
American Co llege of Rheumatol ogy Preliminary  Defini tion of  Improvem ent in Rheumatoi d 
Arthri tis. Arthritis Rheum . 1995, 727-735.
Felson, D.T .; LaV alley, M.P . The ACR20 and Defining a Thresho ld for Response in 
Rheumatic Diseases: T oo Much of a Good Thing. Arthritis Res . Ther . 2014 , 16, 101.
Finckh, A.; Simard, J.F .; Gabay , C.; Guerne, P .-A. Evidence for Differential Acquired D rug
Resistance to Anti-tumor Necrosis Factor Agents in Rheumatoid A rthritis. Ann.Rheum . Dis . 
2006, 65,746-752.
Gaylis, N.; Needell, J.; Sagliani, J. The Effect of Corti cotropin (ACTH 80 U W eekly or 
Biweekly ) in Combinat ion with MTX in Newly Diagnosed RA  Patients From  a Clinical and 

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 67of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtStructural Perspect ive as Measured by CDAI Score, and Osteit is, Synovit is, and Erosions on 
MRI . Annual European Congress of Rh eumatol ogy. Ann. Rheum. Dis. 2015, 74, 1066 -1067. 
Getting, S.J. T argeting Melanocortin Receptors as Potential N ovel 
Therapeut ics. Pharmacol. 
Ther . 2006, 111, 1 -15.
Gillis, T .M.; Crane, M.; Hinkle, C.; W ei, N. AB0502 H.P . Acthar® Gel (Repository 
Corti cotro pin Inject ion)as Adjunct ive Therapy in Patients with Rheumatoid Arthri tis Who 
Have Failed at Least Three Bio logic Therapies W ith Different Modes of Action. Ann.Rheum .
Dis. 2015, 74, 1066.
Graudal , N.; Jürgens, G. Similar Effects of Disease -modifying Ant irheumat ic Drugs, 
Glucocorti coids, and Bio logic Agents on Radiographic Progression in Rheumatoid A rthritis. 
Arthritis Rheum . 
2010 , 62, 2852-2863.
Harris ,E.D. Rheumatoid Arthri tis:Pathophy siology and Implicat ions for Therapy . N.Engl . J.
Med. 1990 , 322, 1277-1289.
Hench, P .S.; Kendall, E.C.; Slocumb, C.H.; Polley , H.F . Effects of Cortisone Acetate and 
Pituitary ACTH on Rheumatoid Arthrit is, Rheumatic Fever and Certain Other C onditions. 
Arch.Intern. Med. 1950, 85, 545 -666.
Imrich, R.; Rovenský, J. Hypotha lamic-pituitary-adrenal Axis in Rheumatoid Arthrit is. Rheum 
Dis. Clin. N. Am. 2010 , 36, 721 -727
Isom äki, H. A.; Mutru, O.; Koota, K. Death Rate and C auses of Death in Pat ients Wit h 
Rheumatoid A rthritis. Scand .J. Rheumatol .1975, 4, 205 -208.
Kirwin, J. R. The Effect of Glucocorticoids on Joint Destruction in Rheumatoid A rthritis. N.
Engl . J.Med. 1995, 333,142-146.
Kyttaris, V.C. Kinase Inhibitors: A New C lass of Ant irheumatic D rugs. Drug Design Develop
.
Therap . 2012, 6, 245-250.
Lal, R.; Bell, S.; Challeng er, R.; Hammock, V .; Nyberg, M.; Decker, D .; et al. 
Pharmacodynamics and T olerabilit y of Repository  Corti cotropin Inject ion in Healt hy Human 
Subjects: Acomparison W ith Intravenous M ethylpredniso lone. J. Clin. Pharmacol . 2015 , 
Open Access Online publicat ion 10 September 2015.

 Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 68of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtLevin, M.H.; Rivo, J.B.; Scott, W .; Figueroa, W .G.; Fred, L.; Barrett, T .F. The Prolonged 
Treatment of Rheumatoid Arthritis W ith Corti sone and Corti cotropin. Am. J.Med. 1953 , 14, 
265-274.
L
évy, L .;Fautre l, B.;Barnetche , T.;Schaeverbeke ,T. Incidence and Risk of Fatal My ocardial 
Infarct ion and Stroke Events in R heumatoi dArthriti s Pat ients. A Systemic R eview of the 
Literature. Clin. Exper .Rheum . 2008, 26, 673 -679.
Mallinckrodt ARD Inc. Acthar Data Compendeum. RD -010- 00 inte rnal data on file.
Mallinckrodt ARD Inc. H.P. Acthar® Gel ;Package Insert: Hazelwood, MO, 2015.
Mallinckrodt ARD Inc. H.P. Acthar® Gel ; Invest igators Brochure: Hazelwood, MO, 2016.
Mason, R.M. Comparative Effects of ACTH and Butazolidin in Rheumatoi d Arthritis. Ann.
Rheum .
Dis. 1953, 12, 82 -87.
Morrow ,T.; Felcone L.H. Defining the Difference: What Makes Bio logics Unique. 
Biotechnol .Health . 2004 , 1, 24-29.
Mountj oy, K.G.; Robbins, L.S.; Mortrud, M.T .; Cone, R.D. The C loning of a Family  of Genes 
That E ncode th e Mel anocorti n Receptors. Scienc e. 1992, 257, 1248 -1251.
Mutru, O.; Koot a, K., Isomäki, H.A. Causes of Death in Autopsied RA  Patients. Scand . J.
Rheumatol. 1976 , 5, 239-40.
Nishim oto, N.; T erao, K.; Mima, T .; Nakahara, H.; T akagi , N; Kakehi, T . Mec hanisms and 
Pathol ogic Significances in Increase in Serum Interleukin -6 (IL -6) and Sol uble IL -6 Receptor 
After Administrati on of  an Anti -IL-6 Receptor Antibody , Tocilizumab, in Patients W ith 
Rheumat oid Arthrit is and Castleman D isease. Blood . 2008 , 112, 3959-3964.
Patel , H.B.; Bombardieri, M.; Sampaio, A.L.F .; D’Acquisto, F .; Gray , M.; Gri eco, P .; et al. 
Anti
-inflammatory  and Ant iosteocl astogenesis Properties of Endogenous Melanocortin 
Receptor T ype 3 in Experimental Arthrit is. FASEB J . 2010, 24, 4835-4843.
Pincus, T .; Callahan L.F .; Sale W.G.; Brooks, A.L.; Pa yne, L.E.; V aughn, W .K. Severe 
Funct ional Declines, W ork Di sabili ty, and Increased Mortalit y in Sevent y-five Rheumatoid 
Arthri tis Patients Studied Over Nine Y ears. Arthritis Rheum . 1984 , 27, 864 -872.

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 69of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtPincus, T . The American Co llege of Rheumatology (ACR) Core Data Set and Derivative 
“Patient Only” Indices to Assess Rheumatoid Arthritis. Clin. Exp.Rheumatol . 2005, 23, S109 -
S113.
Pincus, T . The Clinical Efficacy o f 3 mg/day  Prednisone in Pati ents wi th Rheumatoi d 
Arthri tis: Evidence From  a Rando mized, Double -blind, Placebo -controlled W ithdrawal 
Clinical Trial. Clin
.Exp.Rheumatol . 2011 , 29, S73 -S76.
Prevoo, M.L.L.; van Ho ff, M.A.; Kuper, H.H.; van Leeuwen, M.A.; van de Putte, L.B.A.; van 
Riel, P.L.C.M. Modified Disease Act ivity Scores that Incl ude T went y-eight-joint Counts: 
Development and V alidat ion in a Prospective Longitudinal Study  of Patients W ith 
Rheumatoid Arthrit is. Arthriti s Rheum . 1995, 1, 44-48.
Rath, T .; Rubbert, A. Drug Combinat ions wit h Methotrexate to TreatRheumatoid Arthritis. 
Clin Exp .Rheumatol . 
2010 , 28, S52 -S57.
Redlich, K.; Schett, G.; Steiner, G.; Hayer, S.; W agner, E. F .; Sm olen, J. S. Rheumatoid 
Arthritis Therapy After Tumor Necrosis Factor and Interleukin -1 Blockade. Arthritis Rheum . 
2003 , 48, 3308-3319.
Ruperto, N.; Lovell, D.J.; Quartier, P .; Paz, E.; Rubio -Perez, N.; Silva, C.A.; et al. Abatacept 
in Children W ith Juvenile Idiopathic Arthrit is: A Rando mized , Doubl e-blind, pl acebo -
Controlled W ithdrawal  Trial. Lancet . 2008, 372, 383 -391.
Savage, O.; Davis, P .S.; Chapman, L.; W ickings, J.; Robertson, J.D.; Copeman, W .S.C. 
Corti cotrophin (ACTH) in Rheumatoi d Arthritis. Ann.Rheum . Dis . 1959, 18, 100 - 110.
Schiöth, H.B.; Muceniece, R.; W ikberg, J.E.; Chhajlani, V . Characteri zation of melanocortin 
receptor subt ypes by radio ligand binding analysis. Eur. J. Pharmacol . 1995 , 15, 31 1-317.
Scott, D.L.; W olfe, F.; Huizinga T .W. Rheumatoi d Arthritis. Lancet . 2010, 376, 1094- 1108.
Segurado, O.G.; Sasso, E.H. V ectra DA  for the Objective Measurement of Disease Act ivity in 
Patients wi th Rheumatoi d Arthri tis. Clin. Exp.Rheumatol . 2014 , 32, S29 -S34.
Silverman, M.N.; Sternberg, E.M. Neuroendocrine -immune Interactions in Rh eumatoi d 
Arthri tis: Mechanisms o f Glucocorti coid Resistance. Neur oImmuno. Modulation. 2008, 15, 
19-28.

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 70of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodtSingh, J.A.; Saag, K.G.; Bridges, S.L.; Akl, E.A.; Bannuru, R.R.; Sullivan, M.C.; et al. 2015 
American College of Rheumatology  Guidelines for the Treatm ent of Rheumatoi d Arthritis. 
Arthritis Car e Res . 2016, 68, 1-25
Smolen, J.S.; Landewé, R.; Breedveld, F .C.; Buch, M.; Burm ester, G.; Dougados, M.; et al. 
EULAR R ecommendat ions for the Management of Rheumatoid Arthrit is with Synt hetic and 
Biological Di sease -modifying Ant irheumatic D rugs: 2013 Update. Ann.Rheum .Dis. 2013, 0,
1-18.
Smolen, J.S; Landewé, R.; Breedveld, F .C.; Dougados, M.; Emery , P.; Gau joux-Viala, C.G.; et 
al. EULAR R ecommendat ions for the 
Management of R heumatoi d Arthri tis with Synt hetic 
and Bio logical  Disease -modifying A ntirheum atic Drugs. Ann.Rheum .Dis. 2010 , 69, 964-975.
Solem, J.H.; Röm cke, O. Clinical Evaluat ion of Prolonged ACTH and Cortisone Therapy in 
114 Cases of R heumatoi d Arthritis: A 3 ½ Y ear S tudy. Acta Rheumatol .Scand . 1955 , 1, 243-
249.
Starowi cz, K.; Przewlocka, B. Th e Rol e of Melanocortins and Their Receptors in 
Inflammatory  Processes, Nerve Regenerat ion and N ocicepti on. Life Sci . 2003 , 73, 823-847.
Taylor, R.P .; Lindorfer, M.A. Drug Insight: the Mechanism o f Act ion of Rituximab in 
Autoimmune Disease –The Immune C ompl ex Decoy  Hypothesis. Natur e Clin .Prac .
Rheumatol . 2007 , 3, 86-95.
Townsend, H .B.; Saag, K.G. Glucocortico id Use in Rheumatoid Arthrit is: Benefits, 
Mechanisms, and Risks. Clin. Exp.Rheumatol . 2004 , 22, S77 -S82.
van der Maas, A.; Lie, E.; Christensen, R.; Cho y, E.; de Man, Y .A.; van Riel, P .; et al . 
Construct and Criterion V alidity of Several  Proposed DAS28 -based Rheumatoi dArthri tis 
Flare Criterion: An OMERACT Cohort V alidat ion Study . Ann. Rheum. Dis. 2013, 72. 1800-
1805.
Wolfe, F .; Freundlich, B., Straus, W . Increase in Cardiovascular and Cerebrovascular Disease 
Prevalence in Rheumatoid Arthritis. J
.Rheumatol . 2003, 30, 36-40.
Wolfe, F .; Mi tchell , D.M.; Sibley , J.T. The M ortality o f Rheumatoi d Arthritis.Arthritis 
Rheum. 1994 , 37, 481-494.
Zhang, W .; Bansback, N.; Boonen, A.; Young, A.; Singh, A.; Anis, A.H. V alidit y of the W ork 
Producti vity and Act ivity Impairment Questi onnaire –A General Healt h Version in Pati ents 
With Rheumatoid Arthrit is. Arthritis Res . Ther . 2010, 12, R177.

Acthar Gel (Repository Corticotropin Injection)
Clinical Protocol MNK14 294063
Revision Date: 04 August 2016 Page 71of 71
CONFIDENTIAL
PROPRIET ARYMallinckrodt32Attachments
32.1 Attachment 1: Clinical Laboratory T ests
Serum Chemistry
Alanine aminotransferase (ALT) Chloride
Albumin (total) Creatinine
Alkaline phosphatase Glucose
Aspartate aminotransferase (AST) Phospho rus
Bilirubin (total) Potassium
Blood urea nitrogen Protein, total
Calcium Sodium
CO 2 Uric acid
Diabetes Screen
Hemoglobin A1c
Hormones
Serum and urine beta -human chorionic gonadotropin (pregnancy test)
Hematology Assays
Hematocrit Platelet count
Hemoglobin Red blood cell count
White blood cell count, including differential Absolute neutrophil count
Urinalysis
Blood Nitrite
Clarity Nitrite
Color Protein
Glucose pH
Leukocyte esterase Specific gravity
Ketones
Hepatitis Serology
Hepatitis B core antibody Hepatitis C virus antibody (HCV)
Hepatitis B surface antigen Hepatitis C virus PCR (only if HCV +)
TB Assay
Interferon gamma release assay (IGRA) (obtained at local lab)
